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INTRODUCTION 
SUSTAINED RELEASE DRUG DELIVERY SYSTEM 
       Sustained release dosage form is designed to maintain constant levels of a 
drug in the patient’s bloodstream by releasing the drug over an extended period. 
Maintaining constant blood levels of the drug in the bloodstream increases the 
therapeutic effectiveness of the drug. Drugs are defined precisely under some 
act.( Mithal B.M.,2004) It is the single active chemical entity present in a medicine 
that is used for diagnosis, prevention, treatment, cure of a disease.(Tripathi 
K.D.,2001) Yet to a common man they are just substances which are administered 
to win back an individual from the states of disease or ill health to the normal 
health. The drugs also had mysterious origins and hence the word drug was a 
form of the word called ‘drogues’ meaning of mysterious origin. The word disease 
can be expressed as a combination of ‘dis’ and ‘ease’ indicating absence of 
easiness or well-being or a feeling contrary to the feeling of health.  
      With many drugs the basic goal of therapy is to achieve a steady state blood or 
tissue level that is therapeutically effective and nontoxic for an extended period of 
time. The basic objective in dosage form design is to optimize the delivery of 
medication so as to achieve a measure of control of therapeutic effect in the face 
of uncertain fluctuations in the in-vivo environment in which drug release takes 
place. The appropriate dosage form and correct dose will ensure the maximum 
availability of the drug. The pharmaceutical industry provides a variety of dosage 
forms and dosage levels of particular drugs thus enabling the physician to control 
the onset and duration of drug therapy by altering the dose or mode of 
administration.( Lachmann.L and Lieberman.H.A.,1987) 
Scope of Sustained Drug Delivery  
     Sustained release delivery systems are designed to achieve a prolonged 
therapeutic effect by continuously releasing medication over an extended period of 
time after administration of a single dose. A sustained release dosage forms leads 
to better management of the acute or chronic disease condition. The basic 
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rationale of a sustained drug delivery system is to optimize the bio-pharmaceutic, 
pharmacokinetic and pharmacodynamic properties of a drug in such a way that its 
utility is maximized through reduction in side effects and cure or control of 
condition in the shortest possible time by using smallest quantity to drug, 
administered by the most suitable route. This is usually accomplished by 
maximizing drug availability, i.e., by attempting to attain maximum rate and extent 
of drug absorption; however, control of drug action through formulation also 
implies controlling bioavailability to reduce drug absorption rates. Sustained 
release tablets and capsules are commonly taken only once or twice daily, 
compared with counterpart conventional forms that may have to take three or four 
times daily to achieve the same therapeutic effect.  
      The novel system of drug delivery offer a means of improving the therapeutic 
effectiveness of incorporated drugs by providing sustained, controlled delivery 
and/or targeting the drug to desired site.(Brahmankar,D.M. and sunil B.Jaiswal., 
2002) Oral route has been the most popular and successfully used for sustained 
delivery of drugs because of convenience and ease of administration, greater 
flexibility in dosage form design and ease of production and low cost of such a 
system. The sustained release systems for oral use are mostly solid and based on 
dissolution, diffusion or a combination of both mechanisms in the control of release 
of drugs.   
Sustained release can be achieved by,  
• Incorporating the drug in a carrier system 
 • Altering the structure of the drug at the molecular level 
 • Controlling the input of the drug into the bio-environment to ensure a 
programmed and desirable bio-distribution.  The primary objectives are to ensure 
safety and to improve efficacy of drugs as well as patient compliance. This is 
achieved by better control of plasma   drug levels and less frequent dosing.  
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Advantages of Sustained Release Dosage Form 
i. Frequency of drug administration is reduced. 
ii.  ii. Patient compliance can be improved, and drug administration can be 
made more convenient.  
iii.  The blood level oscillation characteristic of multiple dosing of 
conventional dosage forms is reduced, because a more even blood level 
is maintained. 
iv.  Implicit in the design of sustained release forms, is that the amount of 
drug administered can be reduced, thus maximizing availability with a 
minimum dose. 
v. The safety margin of high-potency drugs can be increased, and the 
incidence of both local and systemic adverse side effects can be 
reduced in sensitive patients. .(Brahmankar,D.M. and sunil B.Jaiswal., 
2002)   
Disadvantages  
i. Administration of sustained release medication does not permit the 
prompt termination of therapy. 
ii.  The physician has less flexibility in adjusting dosage regimens. This is 
fixed by the dosage form regimen. 
iii. Sustained release forms are designed for the normal basis of average 
drug biologic half-lives. Consequently, disease states that alter drug 
disposition, significant patient variation, so forth are not accommodated. 
iv.  Economically more costly processes and equipment are involved in 
manufacturing many sustained release forms.  
Factors to Be Considered for the Formulation of Sustained Release: 
Physicochemical properties  
a) Dose size: For a ideal sustained release formulation the dose size should be 
not more than 500mg.  
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 b) Aqueous solubility: The drug should not be more water soluble or poorly 
soluble; moderate solubility is needed.  
c) Partition co-efficient: Both lipophillic or hydrophilic drugs are difficult to 
process and should possess optimum partition co-efficient. 
 d) Molecule size:  Large molecules show small diffusion co-efficient and may be 
difficult to place into a suitable sustained release system. Drugs of molecular 
weight 500-700 finds no difficult in processing.  
e) Drug stability: It should be significantly stable over an extended period of time 
in the GIT. Generally non-potent drugs are more stable when formulated as 
sustained release form. It should not show high degree of plasma protein binding.  
Route of administration  
     Some routes of administration exert a negative influence on drug efficacy 
especially during chronic administration. Many physiological constrains improved 
by the particular route i.e., GI mobility, blood supply, first pass metabolism.   
Biological properties  
a) Absorption: Drugs that are slowly absorbed or adsorbed with variable 
absorption rate are poor candidates for sustained release. It is assumed that the 
GI transit time of 10-12 hrs, to be ideal for sustained release.  
b) Metabolism:   Rapid metabolism leads to poor formulation in extended release.  
c) Distribution: Drugs with high apparent volumes of distribution which in turn 
influences the rate of elimination for the drug are poor candidates for sustained 
release.  
d) Duration of action Drugs with short half-life and high doses impose a 
constraint because of the dose size needed and those with a long half-life are 
inherently sustained.  
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e) Therapeutic index Drugs with narrow therapeutic range require precise control 
over the blood level of drug placing a constraint on sustained release.  
f) Length of drug therapy Expected length of drug therapy to achieve control or 
curve of ailment is an important factor, in design of control release products.  
g) Disease state: Pathophysiological state of subject plays an important part in 
the design of suitable controlled release delivery system.(Leon lachmann., et 
al.,2002) and (Vyas S.P. and Roop.K., 2002)  
Formulation Methods of Achieving Sustained Drug Release:  
     All sustained release formulations employ a chemical or physical barrier to 
provide slow release of the maintenance dose. Many formulation techniques have 
been used to ‘build’ the barrier into the per-oral dosage form. These techniques 
include the use of coatings, embedding drugs in a wax, fat or plastic matrix, 
microencapsulation, chemical binding to ion-exchange resins and incorporation in 
an osmotic pump. The initial rapidly releasing priming dose of drug may be 
provided by incorporating that portion of the drug in a separate rapidly releasing 
form in the dosage form, for instance, as uncoated, rapidly releasing granules or 
pellets along with coated, slowly releasing granules or pellets in a tablet or hard 
gelatin capsule dosage form.  
      Alternatively, immediate and rapid release of the priming dose has been 
achieved by virtue of the position of that portion of the drug being at the surface of 
a porous wax or plastic matrix. The maintenance dose is provided by drug 
embedded deeper in the porous matrix. 
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 Figure 1.Characteristic representation of plasma concentrations of a 
conventional immediate release dosage form (IR), a sustained release 
dosage form (SR) and an idealized zero-order controlled release (ZOCR) 
dosage form (in combination with a start-up dose). 
     A repeat action tablet may be distinguished from its sustained release 
counterpart by the fact that the repeat action product does not release the drug 
contained therein in a slow controlled manner and consequently doesn’t give a 
plasma concentration-time curve which resembles that of sustained release 
product9. A repeat action tablet usually contains two doses of drug, the first dose 
being released immediately following per-oral administration in order to provide a 
rapid onset of the therapeutic response. The release of the second dose is 
delayed, usually by means of an enteric coat. Consequently when the enteric coat 
surrounding the second dose is breached by the intestinal fluids, the second dose 
is released immediately. (Lee V.H. and Robinson J.P.,1987) 
Classification  
     From a mathematical-modeling point of view, sustained-release systems may 
be classified according to the controlling physical mechanism(s) of release of the 
incorporated drug. We have proposed a convenient method based on the 
mechanism of transport for categorizing them as diffusion-controlled, swelling 
controlled, osmotically controlled, and chemically controlled systems. Sustained 
release of drugs, proteins, and other bioactive agents can be achieved by 
incorporating them either in dissolved or dispersed form in polymers.   
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Diffusion-Controlled drug delivery system: Diffusion is the most common 
mechanism for controlling the release. There are two major types of diffusion-
controlled systems; reservoir devices and membrane devices. Drug release from 
each type of system occurs by diffusion through the macromolecular mesh or 
through the water-filled pores.   
a) Reservoir systems  
      Reservoir systems consist of a polymeric membrane surrounding a core 
containing the drug. The rate-limiting step for drug release is diffusions through the 
outer membrane of the device. To maintain a constant release rate or flux of drug 
from the reservoir, the concentration difference must remain constant. This can be 
achieved by designing a device with excess solid drug in the core. Under these 
conditions, the internal solution in the core remains saturated. This type of device 
is an extremely useful device as it allows for time - independent of zero-order 
release. The major drawback of this type of drug delivery system is the potential 
for catastrophic failure of the device.   
b) Matrix system  
      In matrix devices, the drug is dispersed throughout the three-dimensional 
structure of the polymer. Release occurs due to diffusion of the drug throughout 
the macromolecular mesh or water-filled pores. In these systems, the release rate 
is proportional to time to the one-half power. This is significant in that it is 
impossible to obtain time independent of zero-order release in this type of system 
with simple geometries.   
 C) Swelling –Controlled release systems: In swelling-controlled release 
systems, the drug is dispersed within a glassy polymer. Upon contact with 
biological fluid, the polymer begins to swell. No drug diffusion occurs through the 
polymer phase. As the penetrant enters the glassy polymer, the glass transition 
temperature of the polymer is lowered allowing for relaxations of the 
macromolecular chains. The drug is able to diffuse out of the swollen, rubbery 
area of the polymers. This type of system is characterized by two moving fronts: 
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the front separating the swollen (rubbery) portion and the glassy regions which 
moves with velocity, υ, and the polymer-fluid interface. The rate of drug release is 
controlled by the velocity and position of the front dividing the glassy and rubbery 
portions of the polymer.   
      For true swelling-controlled release systems, the diffusion exponent, n, is 1. 
This type of transport is known as Case II transport and results in zero-order 
release kinetics. However, in some cases, drug release occurs due to a 
combination of macromolecular relaxations and Fickian diffusion. In this case, the 
diffusion exponent is between 0.5 and 1. This   type of transport is known as 
anomalous or non-Fickian transport.   
d) Chemically-Controlled release systems   
      There are two major types of chemically controlled release systems: erodible 
drug delivery systems, and pendent chain systems in erodible systems, drug 
release occurs due to degradation or dissolution of the polymer. In pendent chain 
systems, the drug is affixed to the polymer backbone through degradable linkages. 
As these linkages degrade, the drug is released.  
e) Erodible drug delivery systems:  Erodible drug delivery systems, also known 
as degradable or absorbable release systems, can be either matrix or reservoir 
delivery systems. In reservoir devices, an erodible membrane surrounds the drug 
core. If the membrane erodes significantly after the drug release is complete, the 
dominant mechanism for release would be diffusion. Predictable, zero-order 
release could be obtained with these systems. In some cases, the erosion of the 
membrane occurs simultaneously with the drug release. As the membrane 
thickness decreased due to erosion, the drug delivery rate would also change. 
Finally in some erodible reservoir devices, the drug diffusion in the outer 
membrane does not occur. Under these conditions, drug release does not occur 
until the outer membrane erodes completely. In this type of device, the entire 
contents are released in a single, rapid burst.   
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      For erodible matrix devices, the drug is dispersed within the three-dimensional 
structure of the polymer. Drug release is controlled by drug diffusion through the 
gel of erosion of the polymer. In true erosion-controlled devices, the rate of drug 
diffusion is significantly slower than the rate of polymer erosion, and the drug is 
released as the polymer erodes.  
Environmentally responsive systems   
     Environmentally responsive materials show drastic changes in their swelling 
ratio due to changes in their external pH, temperature, ionic strength, nature and 
composition of the swelling agent, enzymatic or chemical reaction, and Electrical 
or magnetic stimulus In most responsive networks, a critical point exists at which 
this transition occurs.   Responsive materials are unique in that there are many 
different mechanisms for drug release and many different types of release 
systems based on these materials. For instance, in the most cases drug release 
occurs when the gel is highly swollen and is typically controlled by gel swelling, 
drug diffusion, or a coupling of swelling and diffusion. However, in a few instances, 
drug release occurs during gel syneresis by a squeezing mechanism. Also, drug 
release can occur due to erosion of the polymer caused by environmentally 
responsive swelling. Another interesting characteristic about many responsive gels 
is that the mechanism causing the network structural changes can be entirely 
reversible in nature.   
      The ability of these materials to exhibit rapid changes in their swelling behavior 
and pore structure in response to changes in environmental conditions lends these 
materials favorable characteristics as carriers for bioactive agents, including 
peptides and proteins. This type of behavior may allow these materials to serve as 
self-regulated, pulsatile drug delivery system.   
      Initially, the gel is in an environment in which no swelling occurs. As a result, 
very little drug release occurs. However, when the environment changes and the 
gel swells rapid drug release occurs (either by Fickian diffusion, anomalous 
transport, or Case II transport). When the gel collapses as the environment 
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changes, the release can be turned off again. This can be repeated over 
numerous cycles. Such systems could be of extreme importance in the treatment 
of chronic diseases such as diabetes. . (Lee V.H. and Robinson J.P.,1987)  
DIABETES: 
Diabetes Mellitus (DM), often simply referred to as diabetes, is a group of 
metabolic diseases in which a person is mainly characterized by hyperglycemia 
either because of insulin deficiency or because of the resistance shown by the 
cells to insulin produced in the body. It may also be characterized by glycosuria, 
negative nitrogen balance, and sometimes ketonemia. This high blood sugar 
produces the classical symptoms of polyuria (frequent urination), polydipsia 
(increased thirst) and polyphagia (increased hunger). Diabetes Mellitus is 
classified based on the cause or mode of treatments into the following types: 
1. Insulin-dependent diabetes mellitus (IDDM) 
2. Non-insulin-dependent diabetes mellitus (NIDDM) 
3. Gestational diabetes mellitus (GDM) 
4. Secondary to other conditions 
A) Type I (or) Insulin-dependent diabetes mellitus: 
Characterized by the body's failure to produce insulin due to the destruction 
of β cells in the islets of langerhans, and requires the person to inject 
insulin.formerly, it is known as "juvenile diabetes," because it represents a majority 
of the cases in children, teenagers, or young adults, but it can also affect adults. 
Type-1diabetes is mostly caused by autoimmune disorder AND develops because 
the body immune system mistakenly destroys the beta cells in the islet tissue of 
the pancreas that produce insulin due to environmental factors. For the treatment 
of type I insulin must be given subcutaneously or by injecting through any other 
novel routs of administration. 
 
CHAPTER I                                                               INTRODUCTION 
 
COLLEGE OF PHARMACY, MADURAI MEDICAL COLLEGE. Page 11 
 
B) Type II (or)Non-insulin-dependent diabetes mellitus: 
Characterized by insulin resistance, a condition in which cells fail to use 
insulin properly, sometimes combined with an absolute insulin deficiency. People 
can develop type 2 diabetes at any age even during childhood. This form of 
diabetes usually occurs because of abnormality in gluco receptor of β cells, 
Reduced sensitivity of peripheral tissues to insulin, Excess of hyperglycemic 
hormones.Insulin is not sufficient for the treatment of type II diabetes. 
C) Secondary to other conditions 
Diabetes occurring  as secondary to the conditions like Pancreatic disease, 
hormonal disease, Drug or chemical exposure, Insulin receptor abnormalities, 
certain genetic syndromes. 
Signs and Symptoms : 
The classical symptoms of diabetes are, 
 Polyuria (frequent urination), 
Polydipsia (increased thirst)  
 Polyphagia (increased hunger).  
Diabetic ketoacidosis. 
Management 
Diabetes mellitus is a chronic disease which cannot be cured except in very 
specific situations. Management keeps blood sugar levels as close to normal as 
possible, without causing hypoglycemia. This can usually be accomplished 
withdiet, exercise, and use of appropriate medications (insulin in the case of type 
1diabetes, oral antidiabetec medications as well as possibly insulin in type 
2diabetes. 
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Novel Oral Antidiabetecs 
Dipeptidyl  Peptidase (DPP)-4 Inhibitors 
DPP4 inhibitors such as Sitagliptin and Vildagliptin are novel agents for treatment 
of type 2 diabetes. They work by improving β-cell sensitivity to glucose, where by it 
increases glucose-dependent insulin secretion. Gliptins can be used as Mono 
therapy or combined with metformin or sulfonyl ureas.. Gliptins are largely weight 
neutral. 
Examples: Sitagliptin, Vidagliptin. 
MICROENCAPSULTION:  
      Microencapsulation is a process whereby small discrete solid particles or small 
liquid droplets are surrounded and enclosed by an intact shell. Microencapsulation 
is used to modify and delayed drug release form pharmaceutical dosage forms. A 
well designed controlled drug delivery system can overcome some of the problems 
of conventional therapy and enhance the therapeutic efficacy of a particular drug.   
It is the reliable means to deliver the drug to the target site with specificity, if 
modified, and to maintain the desired concentration at the site of interest without 
untoward effects.   
Microspheres received much attention not only for prolonged release, but 
also for targeting of anticancer drugs to the tumor. The intent of the paper is to 
highlight the potential of microencapsulation technique as a vital technique in 
novel drug delivery.  
The Reasons for Microencapsulation  
The reasons for microencapsulation are in some countless cases, the core 
must be isolated from its surroundings, as in vitamins from the deterioration a 
volatile core, improving the handling of a sticky material, or isolation core from 
chemical a attack. The problem may be as simple as masking the taste or odor of 
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the core, or as complex as increasing the selectivity of an adsorption or extraction 
process.   
Fundamental Considerations  
The realization of the potential that microencapsulation offers involves a 
basic understanding of the general properties of microcapsules, such as the 
nature of the core and coating materials, the stability and release characteristics of 
the coated materials and the microencapsulation methods.  
Core Material  
The core material, defined as the specific material to be coated, can be 
liquid or solid in nature. The composition of the core material can be varied as the 
liquid core can include dispersed and/or dissolved material. The solid core can be 
mixture of active constituents, stabilizers, diluents, excipients and release-rate 
retardants or accelerators. The ability to vary the core materials composition 
provides definite flexibility and utilization of this characteristic often allows effectual 
design and development of the desired microcapsules properties.  
Coating Material  
The selection of appropriate coating material decides the physical and 
chemical properties of the resultant microcapsules/microspheres.  
FIGURE-2 Encapsulation 
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While selecting a polymer the product requirements i.e. stabilization, 
reduced volatility, release characteristics, environmental conditions, etc. should be 
taken into consideration. The polymer should be capable of forming a film that is       
cohesive with the core material. It should be chemically compatible, non-reactive 
with the core material and provide the desired coating properties such as strength, 
flexibility, impermeability, optical properties and stability. Generally hydrophilic 
polymers, hydrophobic polymers (or) a combination both are used for the 
microencapsulation process. A number of coating materials gelatin have been 
used successfully; examples of these include polyvinyl alcohol, ethyl cellulose, 
cellulose acetate phthalate and styrene maleic anhydride. The film thickness can 
be varied considerably depending on the surface area of the material to be coated 
and other physical characteristics of the system. The microcapsules may consist 
of a single particle or clusters of particles. After isolation from the liquid 
manufacturing vehicle and drying, the material appears as a free flowing powder. 
The powder is suitable for formulation as compressed tablets, hard gelatin 
capsules, suspensions, and other dosage forms. ( C. Berkland., 2001) 
Multi-particulate Drug Delivery Systems:   
Multi-particulate drug delivery system applies specially to multiple particles 
such as pellets, beads, microspheres, microcapsules. In recent years, multi-
particulate dosage forms or microparticles have gained in popularity for a variety of 
reasons. Considerable research efforts have been spent on oral sustained or 
controlled release multi-particulate drug delivery system due to its advantages 
over monolithic dosage forms.    
Multi-particulate drug delivery systems are mainly oral dosage forms 
consisting of a multiplicity of small discrete units, each exhibit some desired 
characteristics. In these systems, the dosage of the drug substances is divided on 
a plurality of subunit, typically consisting of thousands of spherical particles with 
diameter of 0.05-2.00mm.   
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Thus multi-particulate dosage forms are pharmaceutical formulations in 
which the active substance is present as a number of small independent subunits. 
To deliver the recommended total dose, these subunits are filled into a sachet and 
encapsulated or compressed into a tablet. ( C. Berkland., 2001)    
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MICROSPHERES – A REVIEW 
 INTRODUCTION OF MICROSPHERES  
Introduction: 
      An ideal controlled drug delivery system is the one which delivers the drug at a 
predetermined rate, locally or systemically, for a specified period of time. The 
concept of miroencapsulation was initially utilized in carbonless copy papers. More 
recently it has received increasing attention in pharmaceutical and biomedical 
applications. The first research leading to the development of micro-encapsulation 
procedures for pharmaceuticals was published by Bungenburg de Jong and Kass 
in 1931 and dealt with the preparation of gelatin spheres and the use of gelatin 
coacervation process for coating. In the late 1930s, Green and co-workers of 
National cash register co. Dayton, Ohio, developed the gelatin coacervation 
process. Since then may other coating materials and processes of application 
have been developed by the pharmaceutical industry for the Microsphere of 
medicines. Over the last 25 years numerous patents have been taken out by 
pharmaceutical companies for microencapsulated drugs. Microsphere is a rapidly 
expanding technology. As a process, it is a means of applying relatively thin 
coating to small particles of solids or droplets of liquids and                         
dispersions.( Lachmann.L and Lieberman.H.A.,1987) 
     Microspheres are defined as ‘solid spherical particles containing dispersed 
drug in either solution or microcrystalline form.’ They are ranging in size from 1 to 
1000 micrometer. Microspheres are in strict sense, spherical solid particles. 
Microcapsules are small particles that contains an active agent as a core material 
and coating agent as shell, at present there is no universally accepted size range 
that particle must have in order to be classified as microcapsules. However, many 
workers classify capsules smaller than 1 micrometer as nanocapsules and 
capsules layer more than 1000 micrometer as macroparticles. Commercial 
microcapsules typically have a diameter between 3-80 micrometer and contain 10-
90 weight % cores. Microsphere is a rapidly expanding technology. It is the 
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process of applying relatively thin coatings to small particles of solids or droplets of 
liquids and dispersions. Microsphere provides the means of converting liquids to 
solids, of altering colloidal and surface properties, of providing environmental 
protection and of controlling the release characteristics or availability of coated 
materials(Chien YW.,1990)and(Asha P..,2006). Microsphere is receiving 
considerable attention fundamentally, developmentally and commercially. 
However the terms microcapsule and microspheres are often used synonymously. 
The microspheres are characteristically free flowing powders consisting of proteins 
or synthetic polymers, which are biodegradable in nature, and ideally having a 
particle size less than 200 micrometer. Solid biodegradable microcapsules 
incorporating a drug dispersed or dissolved throughout the particle matrix have the 
potential for the controlled release of drug.  
                                  
Figure-3 (Microencapsulation core material) 
A wide range of core materials have been encapsulated including adhesives, 
agrochemicals, live cells, active enzymes, flavor fragrances, pharmaceuticals, and 
inks.  Most capsule shell materials are organics, polymers, but fats and waxes are 
also used. Microcapsules can have a variety of structures some have a spherical 
geometry with a continuous core region surrounded by a continuous shell as other 
have an irregular geometry and contain a number of small droplets as particles of 
core material. Microcapsules are used in a wide range of oral and injected drug 
formulation. Encapsulated adhesive resins coated on automotive fasteners are 
routinely used to assure that such fasteners are firmly set when installed. 
Microcapsules are also the basis for a number of long acting commercial 
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pesticides and herbicides. Improvement of these products and development of 
new ones is an ongoing process that involves a large number of development 
groups globally. 
Merits of Microsphere:  
     Microsphere offers the ability to do the following. 
1. Microsphere change liquid to solid (powder as particles.) E.g. 
Clofibrate. 
2. Microsphere separate reactive materials from one another and 
handle them in a mix. As store them for a long time. E.g. Mix of 
Aspirin and Chlorfilaramine. 
3. Microsphere curtails any color, taste, odor or toxicity generates by 
core materials. 
4. Microsphere protects materials from environment for examples by 
preventing oxidization. E.g. Vitamin A Palmitate. 
5. Microsphere improves the effective life. 
6. Microsphere holds a liquid on a flat surface by in effect, changing it 
to a solid.  
7. Microsphere controls the releasing conditions. For example, we can 
control the timing of dissolving, volatilization, coloring, release of 
smell, mixing and reaction by changing the size of the capsules, the 
ratio of core materials to shell materials, or the properties of the shell 
materials, such as strength and permeability or by adding 
supplementary materials to core or shell materials.  
8. Microsphere changes the specific gravity. 
9. Microspheres make core materials easy to handle.  
10. Microspheres solidify tacky materials and increase its fluidity. E.g. 
thiamine HCL, riboflavin  
11. Microspheres are normally used to enhance material stability, reduce 
adverse or toxic effects as extend material release for different 
applications in various fields of manufacturing.      
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Demerits of Microsphere:  
1. Drug entrapment is low because some portion of drug is lost in the 
dispersion vehicle. 
2. The industrial scale of microspheres formulation is difficult because 
to maintain size of microspheres at industry level is difficult.  
3. The manufacturing of microspheres involves use of solvents which 
make the process costly.  
4. As compared to the extended release tablets and capsules, the 
manufacturing of microspheres is much more complicated.  
5. Time consuming process as much time period for required for 
emulsification, vaporization of solvent and rigidization of 
microspheres. 
Prerequisites for Ideal Microparticulate Carriers 
The materials utilized for the preparation of microparticulates should ideally fulfill 
the following prerequisites:  
o Longer duration of action  
o Control of content release  
o Increase of therapeutic efficiency  
o Protection of drug  
o Reduction of toxicity  
o Biocompatibility  
o Sterilizability  
o Relative stability  
o Water solubility or dispersability  
o Bioresorbability  
o Targetability  
o Polyvalent 
Fundamental Consideration: 
      Microsphere often involves a basic understanding of the general properties of 
microcapsules, such as the nature of the core and coating materials, the stability 
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and release characteristics of the coated materials and the Microsphere methods. 
The intended physical characters of the encapsulated product and the intended 
use of the final product must also be considered. (Leon Lachman et.al)  
A.Core material  
     The core material, defined as the specific material to be coated, can be liquid or 
solid in nature. The composition of the core material can be varied as the liquid 
core can include dispersed and/or dissolved material. The solid core can be a 
mixture of active constituents, stabilizers, diluents, excipients and release rate 
retardants or accelerators. The core material plays a significant role in the 
production of microcapsules the core material defined as the specific material to 
be coated, can be liquid or solid in nature. It dictates the process as well as the 
polymer used as the coating material. It should be insoluble and non reactive with 
the coating material and the solvent for it water soluble and insoluble solid, water 
insoluble liquid solution and dispersions of liquids can be microencapsulated.  
B. Coating material:  
           Coating material should be capable of forming a film that is cohesive with 
the core materials, be chemically compatible and non reactive with the core 
material and provide the desired coating properties such as strength, flexibility 
impermeability, optical properties and stability. The total thickness of the coatings 
achieved with Microsphere techniques is microscopic in size. The selection of the 
appropriate coating material dictates, to major degree, the resultant physical & 
chemical properties of the microcapsules, and consequently, this selection must 
be given due consideration. The coating material should be capable of forming a 
film that is cohesive with the core material; be chemically compatible and non-
compatible and non reactive with the core material; and provide the desired 
coating properties, such as strength, flexibility, impermeability, optical properties 
and stability. The coatings materials used in Microsphere methods are available; 
to some extend, to in-situ modification. For example, colorants may be added to 
achieve product elegance or masking, or coatings may be plasticized or 
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chemically altered through cross-linking, for instance to achieve controlled 
dissolution or permeability. (Jackson. And Lee, 1991). 
C.   Selected stability, release and other properties  
     Three important areas of current Microsphere application are the stabilization of 
core materials, the control of the release or availability of core materials and 
separation of chemically reactive ingredients within a tablet or powder mixture. A 
wide variety of mechanisms is available to release encapsulated core materials; 
such as disruption of the coating can occur by ressure, shear or abrasion forces, 
permeability changes brought about enzymatically etc., improved gastro tolerability 
of drugs can be obtained by Microsphere. 
   
D.   Physical character of the final product 
       Microcapsules should have desirable physical properties like ability to flow, to 
be compacted or to be suspended and the capsule wall must be capable of 
resisting the pressure during compression etc. 
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TABLE-1 TYPES OF COATING MATERIALS USED TO PRODUCE 
MICROSPHERE 
Class of coating material Examples 
Gums  Gum Arabica, Agar, Sodium alginate, 
Carageenan. 
Carbohydrates  Starch, Agarose, Sucrose, Dextran, 
Corn syrup, Chitoson.  
Cellulose  Carboxy methyl cellulose, Methyl 
cellulose, Ethyl cellulose, Nitro 
cellulose, Acetyl cellulose, Cellulose 
acetate phthalate. 
Lipids  Wax, Paraffin, Stearic acid, Bees wax, 
Oils, Fats, Hardened oil, Diglycerides, 
Monoglycerides.  
Inorganic materials  Cellulose phosphate, Silicates, Clays. 
Proteins Albumins, Gelatin, Collagen, 
Casein, Gluten.  
Chemically modified carbohydrate  Poly (acryl) Dextran, Poly (acryl) starch.  
Non-biodegradable  AEROLEIN, Glycidyl methacrylate, 
Epoxy polymers.  
Bio-degradable  Poly anhydrates, Poly alkyl cyno 
acrylate, Lactides and glycosides and 
their co-polymers. 
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Application:  
1. Microspheres as drug delivery system or protein and peptides.  
2. Microspheres as drug delivery system in cancer therapy.  
3. Microspheres as local delivery system.  
4. Microspheres for targeting of drug.  
5. Microspheres in oral drug delivery.  
6. Sustained drug delivery to brain.  
7. Drug delivery to thee long. 
Methods of Preparation  
1. Solvent removed technique,  
(A)Emulsion – solvent evaporation technique. 
 i) Oil in water (o/w) emulsion solvent evaporation 
 ii) Water in oil (w/o) emulation solvent evaporation 
 iii) Water in oil in water oil water (W/O/W) 
 emulsion solvent evaporation 
 (B)Emulsion solvent extraction.  
(C)Emulsion solvent diffusion.  
2. Coacervation and phase separation technique 
 (A)By temperature change.  
(B)By incompatible polymer addition.  
(C)By non solvent addition  
(D)By salt addition 
 (E)By polymer polymer  interaction  
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(F)By solvent evaporation  
3. Cross – linking technique.  
(A)Chemical cross linking. 
 (B)Thermal cross linking. 
4. Polymerization Technique.  
(A)Normal polymerization.  
(B)Vinyl polymerization.  
(C)Interfacial polymerization. 
 5. Spray drying and spray congealing  
6. Freeze drying technique.  
7. Precipitation technique. 
 8. Multi orifice centrifugal process  
9. Pan coating.  
10.Air suspension coating.  
11.Melt dispersion technique. 
1. Solvent Removed Technique  
(A) Emulsion Solvent evaporation technique         
     This technique is based on the evaporation of the internal phase of an emulsion 
by agitation. 
O/W Emulsification:  
     This technique is particularly suitable for encapsulation of lipophilic active 
principles such as steroid hormone, anti-inflammatory and neuroleptics.  
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     The physicochemical properties of the active principle such as partition 
coefficient, its degree of ionization or its surfactant character play an important role 
in its localization.  
W/O Emulsification:  
E.g: Polymeric microspheres for drug delivery to oral cavity  
Aqueous polymeric solutions were prepared and they were added in a 
dropwise manner to mineral oil containing 1% SPAN80 with continuous stirring.  
The temperature was maintained at 60C for 24hr. allow the evaporation of 
dispersed aqueous phase.  
     The solied polymeric microparticles that separated from the oil on centrifugation 
were washed in hexane and dried in a vaccum dessicator.  
iii)W/O/W Emulsification: 
Active principles to be encapsulated are incorporated in  an aqueous 
solution, which is poured into the casting organic solution of the polymer to form 
the emulsion of type W/O. 
The primary emulsion is itself emulsified in external aqueous compartments 
to multiple emulsion of the type (W/O/W)  
The organic phase acts as barrier between the two aqueous compartments 
preventing diffusion of drug towards the external aqueous phase.  
In some cases gelatine/pectine/agarose are added into aqueous solution of 
active principle in order to hold the active principle in the aqueous internal phase 
by increasing the viscosity of internal phase.  
E.g. Ethyl cellulose microspheres containing diclofenac sodium were 
prepared by this method.  
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      Diclofenac sodium and gelatine were dissolved in water. The emulsion 
obtained was poured in solution of PVA (Polyvinyl Alcohol) in water to make a 
w/o/w emulsion and continuosly stirred. Microspheres were obtained. 
(B)Emulsion Solvent Extraction Technique        
In the emulsification-evaporation method, the organic solvent of dispered 
phase of the emulsion is eliminated in two stages  
Diffusion of the solvent in the continuous phase (Solvent extraction) 
Elimination of the solvent at the continuous phase interphase.  
In theory, if one uses a continuous phase, which will immediately extract the 
solvent of the dispersed phase, the evaporation stage is no longer necessary in 
formulation of microspherers. This can be achieved by Using large volume of 
continuous phase with respect to the dispersed phase. (Eg. 5flouro uracil 
biodegradable micropheres.) By using dispersed phase consisting of cosolvents, 
of which at least one has a great affinity for the continuous phase. One may even 
formulate a continuous phase with two solvents in which one act as solvents 
extractor of the dispersed phase (Eg. PLG microspheres containing diphtheria 
toxoid)  
(C) Emulsion solvent diffusion : 
           The organic solution of drug and polymer is dispersed into aqueous      
medium with constant stirring. During the process solvent first diffuses out and 
then evaporating from the coacervate into the aqueous medium and forms the 
microspheres. As compared to emulsion – solvent evaporation this method is 
simple, quicker and does not required heat or any other harmful solvents. 
 2.Coacervation and Phase Separation Technique  
The process is similar as for the preparation of microspheres.  Microsphere 
by coacervation phase separation is generally attributed to the national cash 
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register (NCR) corporation and the patents of Green et.al. The general outline of 
the processes consists of three steps carried out under continuous agitation.  
     1. Formation of three immiscible chemical phases. 
     2. Disposition of the coating, and  
     3. Rigidization of the coating  
a. By thermal change:  
Phase separation of the dissolved polymer occurs in the form of immiscible 
liquid droplets, and if a core material is present in the system, under proper 
polymer concentration, temperature and agitation conditions, the liquid polymer 
droplets coalesce around the dispersed core material particles, thus forming the 
embryonic microcapsules. As the temperature decreases, one phase becomes 
polymer-poor (the Microsphere vehicle phase) and the second phase. (the coating 
material phase) becomes polymer-rich.  
b. By incompatible polymer addition:  
It involves liquid phase separation of a polymers coating material and 
Microsphere can be accomplished by utilizing the incompatibility of dissimilar 
polymers existing in a common solvent.  
c. By non-solvent addition:  
A liquid that is a non-solvent for a given polymer can be added to a solution 
of the polymer to induce phase separation. The resulting immiscible liquid polymer 
can be utilized to effect Microsphere of an immiscible core material. 
 d. By salt addition:   
There are two types of coacervation: simple and complex. Simple 
coacervation involves the use of only one colloid, e.g. gelatin in water, and 
involves removal of the associated water from around the dispersed colloid by 
agents with a greater affinity for water, such as various alcohols and salts. The 
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dehydrated molecules of polymer tend to aggregate with surrounding molecules to 
form the coacervate. Complex coacervation involves the use of more than one 
colloid. Gelatin and acacia in water are most frequently used, and the coacervation 
is accomplished mainly by charge neutralization of the colloids carrying opposite 
charges rather than by dehydration.  
e. By polymer-polymer interaction:  
The interaction of oppositely charged poly electrolytes can result in the 
formation of a complex having such reduce solubility that phase separation occurs. 
 f. By solvent evaporation:  
The processes are carried out in a liquid manufacturing vehicle. The 
microcapsule coating is dispersed in a volatile solvent, which is dispersed in 
volatile solvents, which is immiscible with the liquid manufacturing vehicle phase. 
A core material to be microencapsulated is dissolved or dispersed in the coating 
polymer solution. With agitation, the core material mixture is dispersed in the liquid 
manufacturing vehicle phase to obtain the appropriate size microcapsule. The 
mixture is then heated if necessary to evaporate the solvent for the polymer. In the 
case in which the core material is dissolved in the coating polymer solution, matrix 
type microcapsules are formed. The solvent evaporation technique to product 
microcapsules is applicable to a wide variety of core materials. The core materials 
may be either water soluble or water insoluble materials. 
3. Cross Linking Technique  
By Chemical and Thermal Cross Linking Microspheres made from natural 
polymers are made by cross linking process. This polymer includes Gelatin, 
Albumin, Starch,  
Dextran In thos technique w/o emulsion is prepared, where Water phase is 
a solution of polymer containing the drug to be incorporated. Oily phase is a 
suitable vegetable oil or oil-mixture containing an oil soluble emulsifier. Once the 
desired emulsion is formed, the water-soluble polymer is solidified by some kind of 
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cross-linking process. This may involve thermal treatment or addition of a cross-
linking agent such as glutaraldehyde to form a stable chemical cross-link as in 
albumin. Eg: Albumin, Chitosan beads prepared by heat stabilization method. 
Theophylline was used as drug. Chemical interactions between the drug, albumin 
and chitosan were evaluated using IR and HPLC. It was found that there was no 
intervention between them. Microspheres with different drug ratios were prepared 
and thermally cross-linked. Invitro release studies were carried out for a period of 
8 hour and compared with pure drug. The microsphere containing 1:1:2 Drug: 
albumin: Chitosan ratio showed maximum release & highest drug entrapment.  
4. Polymerization Technique  
(A) Normal Polymerization:  
The two processes are carried out in a liquied phase. Normal 
polymerization processed and carried out using different techniques as bulk, 
suspension, precipitation, emulsion and miceller polymerization processes. 
     i) In Bulk Polymerization, a monomer or a mixture of monomer along with the 
initiator is usually heated to initiate the polymerization and carry out the process. 
The catalyst or the initiator is added to the reaction mixture to facilitate or 
accelerate the rate of the reaction. The polymer so obtained may be moulded or 
fragmented as microspheres. For loading of drug, adsorptive drug loading or 
adding drug during the process of polymerization may be opted.  
ii) The suspension polymerization, which is also referred to as the bead or pearl 
polymerization is carried out by heating the monomer or mixture of monomers with 
active principles(drugs) as droplets dispersion in a continuous aqueous phase.. 
The droplets may also contain an initiator and other additives.  
iii) The emulsion polymerization differs from the suspension polymerization as due 
to presence of the initiator in the aqueous phase, which later on diffuses to the 
surface of the micelles or the emulsion globules. The bulk polymerization has an 
advantage of formation of the pure polymer, but it also suffers a disadvantage, as 
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it is very difficult to dissipate the heat of reaction, which can adversely affect the 
thermo labile active ingredients. On the other hand the suspension and emulsion 
polymerization can be carried out at lower temperature, since continuous external 
phases is normally water through which heat can easily dissipate. The two 
processes also lead to the formation of the higher molecular weight polymer at 
relatively faster rate. The major disadvantage of suspension and emulsion 
polymerization is, association of polymer with the unreacted monomer and other 
additives.    
 (B) Vinyl polymerization:  
Vinyl monomers are polymerized. The microspheres are formed using 
techniques such as suspension, emulsion, soap less emulsion, dispersion and 
precipitation, seeding and support polymerization. Drug was incorporated within 
the monomers at the initial stage. 
 (C) Interfacial Polymerization:  
Two complementary monomers are taken in a two-phase system and one 
of the phases is dispersed as droplets in another phase, drug is incorporated in 
any one phase and microsphere is obtained when condensation of monomers 
takes place at interface. 
5.   Spray Drying and Spray Congealing Method: 
          Nebulization or spray drying is widely used in the chemical, 
pharmaceauticaland food industries. The principle of spray drying rests on 
atomization of a solution by compressed air or nitrogen through a dessicating 
chamber and drying across a current if warm air.Laboratory spray dryer have  
(1) Drying air inlet + filtration 
 (2) Heating 
 (3) Desiccation chamber 
 (4) Cyclone  
(5) Collector for drying power microspheres  
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(6) Filtration + air outlet.  
(7) Solution, suspension, emulsion to spray  
(8) Compressed or nitrogen air  
(9) Spray nozzle (e.g., pneumatic, ultrasonic)       
Four separate phases may be distinguished  
1. Nebulization of the solution in the form of aerosol  
2. Contact of the nebulized solution with the warm air  
3. Drying of the aerosol 
4. Separation of the diried product and air charged with the solvent Spray 
Congealing: 
Microsphere by spray congealing can be accomplished with spray drying 
equipment when the protective coating is applied as a melt. General process 
variables and conditions are quite similar to those already described, except thet 
the core material is dispersed in a coating material melt rather than a coating 
solution. Coating solidification (and Microsphere) is accomplished by spraying the 
hot mixture into a cool air stream. Waxes, fatty acids and alcohols, polymers and 
sugers, which are solids at room temperature but melt at reasonable temperature, 
are applicable to spray congealing techniques.  
Congealable Dispersed Phase Technique: 
A heated aqueous drug solution can be dispersed in molten wax to form a 
w/o emulsion which is emulsified in a heated external aqueous phase to form a 
w/o/w emulsion. The system is cooled and the microspheres collected. Camuba 
wax and beeswax can be used as coating materials. These wax-coated 
microspheres have been successfully tableted. Another alternative is to rapidly 
reduce the temperature when the primary emulsion is placed in the external 
aqueous phase. 
 
 
 
  CHAPTER II                                          MICROSPHERES – A REVIEW 
 
COLLEGE OF PHARMACY, MADURAI MEDICAL COLLEGE. Page 32 
 
6.  Freeze Drying: 
The freezing of the emulsion is done, the relative freezing points of 
continuous and dispersed phases are important. The continuous phase solvent is 
usually organic and is removed by sublimation at low temperature and pressure. 
7. Precipitation Technique  
The emulsion consists of polar droplets dispersed in non-polar 
medium.Solvent may be removed from the droplets by use of a cosolvent. The 
resultant increase in the polymer drug concentration causes a precipitation forming 
a suspension. Microsphere by Precipitation / Gelation of Na-alginate  
Eg: Glipizide microspheres with a coat consisting of alginate and a 
mucoadhessive polymer such as sodium carboxy-methylcellulose, 
methylcellulose, carbopol and hydroxyl propyl-methylcellulose, were prepared by 
an orifice-ionic gelation process. Glipizide release from alginate-carbopol 
mucoadhessive microspheres was slow and extended over long period(14hr.) of 
time and depended on the composition of coat of the microspheres. 
8. Multiorifice – centrifugal process  
The South-West research institute (SWRI) has developed a mechanical 
process for producing microcapsules that utilizes centrifugal forces to hurl, a core 
material particle through an enveloping Microsphere membrane therapy effecting 
mechanical Microsphere. Processing variables include the rotational speed of the 
cylinder, the flow rate of the core and coating materials, the concentration and 
viscosity of the coating material and the viscosity and surface tension of the core 
material. This method is capable of microencapsulating liquids and solids of varied 
size ranges, with diverse coating materials.  
9. Pan coating: 
The microcapsulation of relatively large particles by pan coating method 
has become wide spread in the pharmaceutical industry and solid particles greater 
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than 600 µg in size are generally considered essential for effective coating. The 
coating is applied as a solution or as an automized spray to the desired solid core 
passed over the coated materials during coatings are being applied in the coating 
pans.  
10. Air-suspension coating:  
Air-suspension coating of particles by solutions or melts gives better control 
and flexibility. The particles are coated while suspended in an upward-moving air 
stream. They are supported by a perforated plate having different patterns of holes 
inside and outside a cylindrical insert. Just sufficient air is permitted to rise through 
the outer annular space to fluidize the settling particles. Most of the rising air 
(usually heated) flows inside the cylinder, causing the particles to rise rapidly. At 
the top, as the air stream diverges and slows, they settle back onto the outer bed 
and move downward to repeat the cycle. The particles pass through the inner 
cylinder many times in a few minutes. 
11. Melt-dispersion technique: 
In this technique the coating material is melted by heating upto 80oC. The 
drug is suspended in it and then emulsified in water containing emulsifying agent 
at 80oC under stirring. Microcapsules are formed as the temperature of the system 
reaches to room temperature.   
Evaluation of Microspheres: 
The characterization of microcapsule carrier is an important phenomenon, 
which helps to design a suitable carrier for the proteins, drug or antigen delivery. 
The parameters that are generally evaluated for characterization of microcapsules 
are:  
  1. Microsphere morphology  
  2. Microsphere size and shape  
  3. Drug content or drug loading  
  4. Mass loss and degree of hydration  
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  5. In-Vitro drug release study  
  6. Density determination.  
  7. Iso electric point.  
  8. Capture efficiency.  
  9. Contact angle. 
  
1. Microsphere morphology:   
     The internal and external morphologies of microspheres were visualized using 
SEM (Scanning electron Microscopy), Electron microscopy, and Scanning 
tunneling microscopy. Fourier transforms Raman spectroscopy or X-ray 
photoelectron spectroscopy may be used to determine if any of the material which 
should have been entrapped is present on the surface and if any other 
contaminates are present. Other surface characterization techniques include 
surface charge analysis using microelectronphoresis.Surface charge can provide 
information regarding microspheres aggregation. Surface charge is an important 
parameter with respect to the interaction of microspheres within the body. 
Following i.v Injection, microspheres can be taken by the macrophage or 
monocyte cells present in the plasma; surface charge is one of the parameters, 
which determines whether this takes place. Surface forces are important in the 
entrapment, wetting and adhesion of core material by the coating material. The 
wettability of solids by different liquids is assessed by contact angle 
measurements. When wetting of core material is poor, it is difficult or impossible to 
form microspheres 
.2. Microsphere size  
     The most widely used procedure to visualize microcapsule are conventional 
light microscopy, and Scanning electron microscopy (SEM). Both techniques can 
be used to determine the shape and outer structure of microcapsule. SEM 
provides higher resolution in contrast to the light microscopy. It allows investigation 
of the microsphere surfaces and after particles are cross sectioned, it can also be 
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used for the investigation of double walled systems. Confocal laser scanning 
microscopy (CLSM) is applied as a nondestructive visualization technique, which 
allows characterization of structures not only on surface, but also inside particle. 
Different methods used are:  
a. Light microscopy  
b. Resistance blockage techniques (Coulter analysis) 
c. Light blockage techniques  
d. Light scattering  
e. Laser diffraction analysis  
     Microscopic method For particles less than 1µm, photon correlation 
spectroscopy is used. Average particle size is calculated from SEM 
photomicrographs. The size distribution can be carried out by optical microscopy, 
or using a Beckman-Coulter counter multisizer. A 100 micrometer orifice is 
generally used and at least 50000 particles were counted for each sample. The 
particle size distribution of the microspheres is also determined by laser scattering 
instrument. 
3. Drug loading or drug content  
     Differential scanning calorimetric and U.V. Spectrophotometric methods were 
employed to verify the presence of drug in microspheres and its chemical stability. 
The differential scanning calorimeter was used to obtain the thermograms of 
various formulations.  
Encapsulation Efficiency is defined as: E% = (La/Lt)*100  
La = actual loading  
Lt = Theoretical loading 
4. Mass loss and degree of hydration: 
      The wet microspheres were weighed accurately (Wet wt. = Ww) dried for 48 
hrs under reduced pressures at room temperature and weighted again. (dry wt. = 
Wd)   
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MR (%) = (Wd/Ww)*100  
DH = (Ww – Wd) Wd  
 Where, 
      MR = Mass remaining,  
      DH = Degree of hydration,  
     Wd = dry weight,  
     Ww = Initial wt of microspheres  
5. In vitro drug release 
      To find out the in vitro release the most commonly used techniques is as 
follows: In vitro release profile of drug from microspheres is examined in 
Phosphate buffer of pH 7.4 from 3-10 hr using the rotating basket method 
specified in USP XX1 AT 100 rpm. Microspheres equivalent to 50mg of drug were 
suspended in the dissolution medium and the medium was maintained at 37oC , 5 
ml of samples were withdrawn periodically at intervals of half an hour ad same 
volume of fresh medium was replaced in to the breaker. The concentration of drug 
released at different time intervals was then determined by measuring the 
absorbance using spectrophotometer. 
6. Density determination 
      The density of the microcapsule can be measured by using a multi volume 
pychnometer. Accurately weighed sample in a cup is placed in pychnometer, 
helium is introduced at a constant pressure in chamber and allowed to expand. 
The expansion results in a decrease in pressure within the chamber. From two 
pressure readings the volume and hence density of microcapsule can be 
determined. 
7. Isoelectric point:  
     The micro electrophoresis is an apparatus used to measure electrophoretic 
mobility of microsphere from which the isoelectric point can be determined. The 
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electrophoretic mobility can be related to surface contained charge, ionisable 
behavior or ion absorption nature of microsphere.   
8. Capture efficiency  
The capture efficiency of microcapsule or the percent drug entrapment can be 
determined by allowing washed microcapsule to lyse. The lysate is then subjected 
to determination of active constituents as per monograph. The percent 
encapsulation efficiency is calculated using following equation  
       % Entrapment = actual content/theoretical content x 100   
9. Contact angle  
     The angle of contact is measured to determine the wetting property of 
microcapsule. It determines the nature of microsphere in terms of hydrophilicity or 
hydrophobicity. The angle of contact is measured at the solid/air/water surface by 
placing a droplet in circular cell mounted above the objective of inverted 
microscope. Contact angle is measured at 20oC within a minute of decomposition 
of microspheres. 
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LITERATURE REVIEW 
 [H. Abdul Rahman et al., 2017] prepared chitosan microspheres for the 
delivery of chemotherapeutic agents, using paclitaxel as a model.  Chitosan had 
unique physiochemical and biological features that suggested as a good candidate 
for the development of safe and effective drug delivery systems.  The development 
of formulations of targeted delivery systems for the chemotherapeutic agents like 
paclitaxel can potentially alleviate the systemic cytotoxicity as well as directing 
therapy to the specific lesions.  The main aim of this work was to critically evaluate 
the use of chitosan microspheres as a drug delivery system to enhance paclitaxel 
distribution and efficacy in specific targeted sites.  The medium molecular weight 
of chitosan microspheres exhibited the highest paclitaxel dissolution rate because 
of the highest aqueous perfusable microspheres, where 90% of the drug could be 
released from the formulation and pH of the formulation and it was between 21-
83.7% then the cumulative release amount was increased within 24hours. 
 [Banasmita K., et al., 2017] formulated and evaluated metronidazole 
microspheres-loaded bioadhesive vaginal gel to ensure longer residence time at 
the infection site, providing a favourable release profile for the drug.  Microspheres 
were prepared by solvent evaporation method in various ratios of metronidazole to 
poly-ε-caprolactone(PCL).  The optimized batch of microspheres F4 showed 
entrapment efficiency of 72.62%, solubility 1.5mg/ml, and partition coefficient of 
0.12.  Particle size of all the formulations was observed below 100µm.  Regular 
and spherical particles were observed in the SEM photomicrographs.  The 
optimized gel formulation G5 showed viscosity of 7538cps at 100 rpm, gel strength 
recorded as 35 secobds for a 1000 mg load and spreadability of 4.6 
g.cm/seconds.  G5 showed 82.4%drug release at 10 hours and mucoadhesive 
strength of 6.5±1.2 g.  The study results suggested that metronidazole-loaded PCL 
microspheres in mucoadhesive gel would provide a mean for sustained treatment 
of vaginal infections. 
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     [Daniel G et al., 2017] designed and developed a novel sitagliptin-
loaded transdermal patch for diabetes treatment.  Sitagliptin was formulated in a 
gel-type reservoir on a transdermal patch device, optimized by a mathematical 
simulation methodology, and experimentally validated in vitro using a franz cell 
apparatus.  The mathematical model determined optimal design parameters which 
included 1% w/w acellulose as drug reservoir, transdermal patch rate control 
membranes, 1.25 mM  initial drug concentration, 2 mL initial volume, and 4.52 cm2 
patch area.  The optimized reservoir formulation was then fabricated in the 
transdermal patch system and tested using Franz cell to validate the simulation.  
The experimental results from the fabricated transdermal patch system indicated 
that sitagliptin can be formulated in a patch to achieve the target effective plasma 
drug concentration in less than one hour and is able to sustain glucose control for 
over 24 hours.   
 [Bhagat BV., et al., 2016] formulated and evaluated the rifampicin loaded 
microspheres by non-aqueous solvent evaporation method.  Ethyl cellulose and 
carboxy methyl cellulose were used as the retardant materials.  The prepared 
microspheres were red, free flowing and spherical in shape.  It was observed that 
the increase in concentration of the polymer, increases the mean particle size of 
the microspheres.  The mean particle size of the prepared microspheres was 
found to be 40.14 ± 1.17 to 53.88 ± 2.1µm.  The maximum yield of the 
microspheres was found to be 87.27% and the encapsulation efficiency was found 
to be 27%. In-vitro release studies indicated that the formulation F1 released 
80.567% of rifampicin at the end of 12 hours.  Thus the prepared microspheres 
proved to be a potential candidate as a microparticulate drug delivery in this area 
of patent novel. 
 [Hitesh K., et al., 2016] fabricated and characterized metformin 
hydrochloride floating microspheres using Eudragit RS 100 as a retardant 
polymer, by non-aqueous solvent evaporation method.  The influence of 
formulation factors on particle size, encapsulation efficiency and in vitro release 
characteristics of the microspheres were investigated.  SEM showed that the 
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microspheres were spherical and smooth in texture.  Drug entrapment efficiency 
was found to increase with increase in polymer concentration.  At 3:1 polymer: 
drug ratio ES3, drug entrapment efficiency was found to be maximum 79.12%, 
buoyancy of optimized formulation ES3 found to be 95% and they were in the size 
range of 200-300 µm by all formulation.  The in-vitro drug release profile was 
biphasic with an initial burst release 19.23% in 1hour attributed to surface 
associated drug, followed by a slower release phase, 83.27% drug release after 
12 hours there was a sustained release of a drug at a constant rate. 
[Ramya B and Krishna A., 2015]prepared and evaluated floating 
microspheres of omeprazole by solvent evaporation method.  Process parameters 
such as stirring speed, stirring time and organic to aqueous phase ratio were 
optimized.  Floating microspheres were prepared by non-effervescent system.  
Ethyl cellulose and Eudragit S 100 used as a swollen polymers.  F4 formulation 
showing highest entrapment efficiency, was found to be 96.8%, drug content was 
60.9%.  In a time period of 12 hours 70.3% of drug had been released from F10 
formulation.  The percentage of buoyancy was found to be 70.3%.  From the 
results , 1:30 drug to polymer ratio at 1:5 organic to aqueous phase ratio 
omeprazole could be formulated with good entrapment efficiency, sustained 
release property and highest percentage of buoyancy. 
 [Irin D., et al.,2015] formulated and evaluated glibenclamide microspheres 
using different polymers such as ethyl cellulose, eudragit RS/RL 100  and 
methocel K15 by non-aqueous solvent evaporation technique.  The maximum and 
minimum release of drug was observed 90.99% and 71.98%.  Percent of actual 
drug entrapment varied from 7.89% to 15.36% and percent of drug entrapment 
efficiency varied from 69.23% to 98.21%.  The in-vitro studies showed that after 
the end of 8 hours of dissolution, the release drug from microspheres was 98.21%. 
    
 
 
CHAPTER III                                                  LITERATURE REVIEW 
 
COLLEGE OF PHARMACY, MADURAI MEDICAL COLLEGE. Page 41 
 
 [Prasanthi S., et al., 2015] formulated and evaluated sitagliptin phosphate 
and simvastatin bilayered tablets by direct compression technique.  Ten 
formulations of sitagliptin phosphate and simvastatin bilayered tablets were 
prepared by varying the ratios of polymers in the sitagliptin phosphate layer and 
simvastatin layer F1 to F10 by direct compression technique.  All the powdered 
blends of formulations were evaluated for pre-compression parameters for flow 
properties such as angle of repose, tapped density, compressibility index and post 
compression parameters such as thickness, weight variation, friability, hardness, 
drug content, in-vitro disintegration and dissolution studies and they were found to 
be within USP limits.  Among all formulations F7 was optimized as best 
formulation.  F7 formulaltion showed 97.23% for sitagliptin phosphate and 
simvastatin 98.32%, maximum drug release at the end of 45 minutes. 
[Tanvi P., et al.,2015] formulated and evaluated floating tablets of 
sitagliptin phosphate prepared by employing different polymers like guar gum, 
carbopol 940, and HPMC  and magnesium stearate by effervescent technique.  
Sodium bicarbonate and citric acid were incorporated as gas generating agent.  
The tablets were produced by direct compression method.  The floating tablets 
were evaluated for uniformity of weight, hardness, friability, drug content, swelling 
studies, dissolution studies, disintegration studies and stability studies.  All the 
prepared batches showed good results of in-vitro studies of tablets.  It was aimed 
to prepare for prolong residence in the stomach over conventional gastro-retentive 
approaches. 
[Sunita Shakya., 2015] formulated and optimized immediate release tablet 
of sitagliptin phosphate using response surface methodology for the management 
of type-II diabetes mellitus.  Different formulations of immediate release were 
prepared by applying 2 factor 2 level Central Composite Design using Minitab 16 
which gave 13 formulations for each layer.  The amount of Sodium Starch 
Glycollate(SSG) and croscarmellose sodium in IR layer were used as independent 
variables and the percent drug release at 15 minutes were selected as dependant 
variables for optimization.  Based on the in-vitro dissolution data, the composition 
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of formulation with optimum drug release for immediate release were identified 
and employed to formulate optimized tablets followed by its evaluation.  All the 
physico-chemical parameters of the tablets were found satisfactory.  The 
optimized sitagliptin phosphate IR tablet disintegrated in 14 seconds and showed 
an initial release of sitagliptin 99.072% within 15 minutes. 
 [Alini D., et al., 2014] developed and validated the conditions for the 
dissolution method for coated tablets based on in-vivo data for improving medium 
sensitivity by investigating a possible in vivo- in vitro correlation.  Several 
parameters were tested to develop the method, and the following conditions were 
considered satisfactory: pH 6.8 phosphate buffer, 900ml of dissolution medium, 
temperature at 37 ± 1oc, paddle apparatus, and rotation speed at 50 rpm.  The 
dissolved percentage of sitagliptin was quantified by high performance liquid 
chromatography.   The method is linear in the range of 10.0-70.0 µg/ml, precise, 
with RSD values less than 2%, and accurate.  The dissolution method as 
developed and validated supplied a good IVIVC when employing pH 6.8 phosphate 
buffer medium, which can be used in quality control of sitagliptin coated tablets 
since no official method has been described. 
 [Rashmi R., et al., 2014] developed and evaluated sustained release 
microspheres of glibenclamide using ethyl cellulose N 100 as a rate retardant 
polymer, by emulsion solvent evaporation method.  SEM studies showed that the 
microspheres were spherical and porous in nature, the mean particle size ranging 
from 111.3 µm to 140.12µm.  The batch EC5 showed highest drug entrapment 
efficiency of about 82.33%. The in-vitro release studies revealed that the drug 
release was sustained up to 24 hours. The in-vivo studies were performed in 
healthy rabbits to analyze the floating efficiency of microspheres.  Microspheres of 
glibenclamide were prepared successfully and could help to manage better the 
complications involved in type II diabetes. 
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 [Pavan Kumar and Sree Priya., et al., 2014] formulated and evaluated 
floating microspheres of dextromethorphan hydrobromide by solvent evaporation 
technique using polymers like ethyl cellulose and hydroxyl propyl methyl cellulose 
in different ratios.  The increased concentration of polymer affected the particle 
size, percentage yield, in-vitro buoyancy and drug release from the microspheres.  
Percentage yield of microspheres was found up to 71.16%.  The formulated 
microspheres were free flowing with good flow properties.  SEM of optimized 
formulation F3 confirmed spherical structure of microspheres with pores on the 
rough surface and the particles were of the size range from 112-224 µm.  The 
floating microspheres of optimized formulation F3, exhibited the prolonged drug 
release of 99.61% in sustained manner up to 12 hours and remain buoyant more 
than 12 hours.  The drug release mechanism from the floating microspheres was 
found to be anamolus type(non-fickian diffusion) and followed Higuchi kinetics. 
 [Ramesh Y., et al., 2013] formulated and evaluated floating microspheres 
of norfloxacin by non-aqueous solvent diffusion method using polymers hydroxyl 
propyl methyl cellulose and ethyl cellulose.  The SEM photographs of the 
microspheres revealed that the microspheres were spherical with smooth surface 
and slightly aggregated and size range was 340-425 µm.  The formulation NF-XIII 
showed highest percentage yield 98.5%, and highest entrapment efficiency 99%.  
The buoyancy results indicated that all formulations floated for more than 12 hours 
over the surface of the dissolution medium without any apparent gelation.  The in-
vitro drug release revealed that batch NF-XIII was having 98.8% cumulative 
release at the end of 10th hour when compared with all batches due to increase in 
polymer concentration as seen in all formulation. 
 [Saudagar R B et al., 2013] formulated and evaluated sustained release 
microspheres of Ropinirole hydrochloride using ethyl cellulose by w/o type 
emulsion solvent evaporation technique and bees wax based microspheres was 
prepared by spray drying technique.  Thus the sustained release  microsphere of 
ropinirole hydrochloride for 12 hours were successfullu designed, optimized and 
characterized by using potential polymers of ethyl cellulose and beeswax. 
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 [Navneet Garud and Akanksha., 2012] formulated metformin 
microspheres by non-aqueous solvent evaporation method using various polymers 
including ethyl cellulose, hydroxyl propyl methyl cellulose, carbopol 934P and 
chitosan.  The effect of process variables, viz, drug/polymer ratio, stirring rate and 
type of polymer on the mean particle size, and drug release of the microspheres 
were studied.  It was observed that as the stirring speed increased from 600 to 
1800 rpm, microsphere size decreased and hence drug release rate increased.  
Drug release rate at 1:2 drug: polymer for microspheres produced at a stirring rate 
of 1200 rpm was in the following order: carbopol 934P>HPMC>ethyl 
cellulose>chitosan.   The formulations containing carbopol 934P and HPMC 
released drug faster than chitosan microspheres,  Amongst the developed 
microspheres, CH3 formulation exhibited maximum prolonged drug release at 
gastrointestinal pH or at least 15 hours. This oral sustained metformin formulation 
could potentially improve the bioavailability of the drug as well as patient 
compliance.  
 [Manish D., et al., 2012] formulated and evaluated floating microspheres 
of metformin hydrochloride using hydroxyl propyl methyl cellulose and Eudragit RS 
100 polymers by emulsion solvent evaporation technique.  The average particle 
size of microspheres were between 608 and 864 µm.  The SEM studies showed 
microspheres were spherical, discrete and having a rough surface.  The in-vitro 
drug release studies indicated that the percent drug release rate for F4 formulation 
showed high release than all formulations. 
 [Lydia F., et al., 2011] achieved controlled delivery of Gentamicin using 
poly(3-hydroxybutyrate) microspheres using a solid-in-oil-water (s/o/w) technique.  
For this study, several parameters such as polymer concentration, surfactant, and 
stirring rates were varied in order to determine the effect on microsphere 
characteristics.  The average size of the microspheres was in the range of 2µm to 
1.54µm, low stirring speed of 300rpm produced slightly larger microspheres when 
compared to the smaller microspheres produced when the stirring velocity was 
increased to 800rpm.  The surface morphology of the microspheres appeared 
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smooth when observed under SEM.  The microspheres exhibiting the highest 
encapsulation efficiency was 48%.  The in-vitro release of gentamicin was 
bimodal, an initial burst release was observed followed by a diffusion mediated 
sustained release, finally after 20 hours, the cumulative drug release was 95.33%. 
 [Saritha D., et al., 2011] formulated and evaluated ramipril microspheres 
produced by the non-aqueous emulsification solvent evaporation method.  The 
microspheres were prepared using polymethacrylate polymers and hypermellose.  
The impact of different factors such as stirring rate, polymer concentration, and 
volume at processing medium on the characteristics of the microspheres were 
investigated.  Surface of the microspheres was investigated by SEM, showed they 
were spherical in shape and exhibited porous surface it suggested that the drug 
was released through pores and the mechanism of drug release was diffusion 
controlled.  The mean particle size of the formulation F1 to F4 was found to be 
increased from 52 µm ± 1.5 to 100 µm ± 0.52 due to increasing polymer 
concentration.  The entrapment efficiency was found to be increase from 52.43% 
±0.45 to 23.19% ± 0.66 this could be due to the increased viscosity in a fixed 
volume of solvent as the drug to polymer ratio increased.  In-vitro release studies 
were showed the increase in drug release rate from 20th & 18th hours was 
observed due to higher migration of drug to the surface, increasing stirring speed, 
decreased particle size and increased larger available surface area.  Eudragit RL 
100 polymer increased the porosity of the matrix and they accelerated the drug 
release. 
 [Sudhamani . et al.,2011] prepared and evaluated of ethyl cellulose 
microspheres of ibuprofen for sustained drug delivery.  These ethyl cellulose 
microspheres were prepared by the solvent evaporation method. The prepared 
microspheres were subjected to various evaluation and in-vitro release studies. 
Highest percentage of loading was obtained by increasing the amount of ibuprofen 
with respect to polymer. The particle sizes of the prepared microspheres were 
determined.   
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 [Kumar,Ankit .et al.,2011]  evaluated  microencapsulation this approach 
facilitates accurate delivery of small quantities of potent drugs, reduced drug 
concentrations at sites other than the target organ or tissue and protection of labile 
compounds before and after administration and prior to appearance at the site of 
action. Microencapsulation system offers potential advantages over conventional 
drug delivery systems. Microspheres and microparticales are a unique carrier 
system for various pharmaceuticals dosage form. 
 [Vijaya Ramesh et al.,2011] used different polymers for the development 
of microparticles for controlled release of antibiotic drug ciprofloxacin. 
Microspheres were prepared by emulsion solvent evaporation technique. Attempts 
are also made to increase the entrapment efficiency by changing experimental 
variables.  
 [Chinna B., et al., 2010] formulated and evaluated indomethacin 
microspheres using natural and synthetic polymer such as egg albumin, ethyl 
cellulose, eudragit L 100 as the retardant materials for controlled release 
preparation of a highly water- soluble drug, indomethacin.  Microspheres were 
prepared by solvent evaporation method using an acetone/liquid paraffin system 
and phase separation co-acervation method.  The prepared microspheres were 
evaluated  and characterized, the mean particle size of the microspheres was 
found in the range of 150 to 400µm.  The drug-loaded microspheres showed 70-
86% of entrapment and release was extended up to 6 to 8 hours releasing 86% 
the total drug from the microspheres.    The release of indomethacin was 
influenced by the drug to polymer ratio and particle size was found to be both 
diffusion and dissolution controlled. 
 [Subbiah G., et al., 2010] formulated and evaluated controlled release 
formulation of idarubicin microspheres using biodegradable hydrophilic and 
hydrophobic polymer mixtures such as ethyl cellulose and HPMC by using solvent 
evaporation method.  By increasing the concentration of ethyl cellulose the mean 
particle size also increased , with change in the speed of rotation, there is an 
influence on the size of the microspheres that varied with increase in size with 
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decrease in rotation and was in the range between 134.0±9.0 to 424.7±11.2 µm 
for 1000rpm and 500rpm respectively.  But the entrapment capacity did not show 
much significant change in change in speed of rotation falling between 54% and 
62%.  The release of idarubicin microspheres showed Higuchi’s square root 
model.  This model showed that the idarubicin can be attempted to maintain 
sustained release and reducing the side effects produced by the drug. 
 [Phutane P., et al., 2010] formulated and evaluated novel sustained 
release microspheres of glipizide using Eudragit RS 100 and ethyl cellulose as a 
rate retardant polymers by the emulsion solvent diffusion-evaporation technique by 
using the modified ethanol,-dichloromethane co-solvent system.  SEM indicated 
that the microspheres were spherical with smooth surface and not aggregated.  
Maximum encapsulation efficiency was observed of the batch F3 was 94.84%.  
The combination of Eudragit RS 100 and ethyl cellulose had been achieved in 
batch F3 where extended release of drug for approximately 12 hours had been 
obtained  and the %drug release at 12th hour was 96.76% 
[YeM. et al.,2010] shown that biodegradable microparticles can be applied 
in long-term protein delivery. The conventional way of delivering a protein drug 
needs daily, sometimes multiple, injections to achieve its therapeutic 
effectiveness. To perfect patient compliance and ease, sustained release dosage 
forms have been developed.This section examines the properties of protein-
loaded microparticles, in specific, protein loading and release characteristics from 
PLGA microparticles.  
 [Shashank tiwari. et al.,2010] formulated micoencapsulation by solvent 
evaporation method (study of effect process variables) the properties of poly 
(lacticacid) (poly lactic co glycolic acid) the effect of this microencapsulation is 
successful .and to get a desire release rate and highest drug loading.    
 [Anand,Chirag. et al.,2010] formulated and evaluated of floating  
micropsheres of captopril for prolong gastric residence time. Floating 
microspheres was formulated using biocompatible polymers like Eudragit S100 
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and Ethyl cellulose in different proportions by solvent evaporation technique. The 
prepared microspheres were evaluated for percentage yield, micromeritic 
properties, particle size, morphology, drug entrapment, buoyancy studies, In vitro 
drug release studies, practical yield of the microspheres.   
 [Umamaheshwari. et al.,2010] developed effective drug delivery systems 
for the treatment of Helicobacter pylori infection using polycarbonate (PC) floating 
microspheres as drug carriers. In an effort to augment the anti-H. pylori effect of 
acetohydroxamic acid (AHA), floating PC microspheres, which have the ability to 
reside in the gastrointestinal (GI) tract for an extended period, were prepared by 
emulsion (O/W) solvent evaporation technique. The effect of PC concentration on 
the morphology, particle size, entrapment efficiency and drug release rate was 
studied. Invitro studies confirmed the excellent floating properties of PC 
microspheres. In conclusion, the floating microspheres more effectively cleared H. 
pylori from the GI tract than the drug because of the prolonged gastric residence 
time resulting from the excellent buoyancy of the PC. 
 [Kannan k., et al., 2009] formulated and evaluated sustained release 
microspheres of acetazolamide by solvent evaporation technique using Eudragit 
RL/RS as a rate retardant polymer.  Spherical particles were obtained, when the 
polymer and drug ratio was increased (2:1, 3:1) at stirring speed 750 rpm.  The 
average size of the microspheres was found as 250µm in all the formulations.  The 
in-vitro release of the drug from microspheres showed that the release rates were 
very slow in Eudragit RS and in the release rate is fast in the microspheres made 
by Eudragit RL.  So the combination of the polymers Eudragit RS and Eudragit RL 
gives desired release of drug from the microspheres. 
 [Durgacharan A., et al., 2009] formulated and evaluated controlled 
release microspheres of isosorbide dinitrate by non-aqueous emulsification solvent 
evaporation method using acrycoat S 100 as matrix polymer.  The mean particle 
size of the microspheres was in the range 140.2 ±8.3 to 248.7 ± 17.24 µm. SEM 
showed that they were spherical with a smooth surface and exhibited a range of 
sizes within each batch.  The incorporation efficiency was showed higher at 
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89.24% ± 2.1 in A3 batch.  The in-vitro release studies were performed for 12 
hours and the cumulative release of isosorbide dinitrate significantly decreased 
with increasing acrycoat S 100 polymer concentration.  Smaller microspheres 
were formed at lower polymer concentration and had a larger surface area 
exposed to dissolution medium, release was higher in the case of microspheres 
prepared at a higher agitation speed but at low agitation speed the release rate 
was slow.  
 [Vadhana singh et al.,2009] Develop the hollow microspheres as a new 
dosage  form of floating drug delivery system with prolonged stomach retention 
time.  Hollow microspheres containing ranitidine hydrochloride were prepared by 
solvent evaporation method using Eudragit RLPO dissolved in a mixture of 
dichloromethane and ethanol. Hollow microspheres could prolong drug release 
time (approximately 24 hrs) and float over stimulate gastric fluid for more than 
12hrs.   
[Kem et al.,2009] produced uniform microspheres and double-wall  
microspheres capable of efficiently encapsulating model drugs. Of primary 
importance was the ability of monodisperse microsphere formulations. 
Monodisperse PPF microspheres and core-shell microparticles offer advantages in 
reproducibility, control, and consistency that may provide valuable assistance in 
designing advanced drug delivery systems to achieve precise control of the 
particle size and reproducibly fabricate nanocapsules the technology. 
 [Om praksh et al., 2009] Evaluated rosin polymer, Rosin application 
agent, microencapsulating agent. It had been found anti-inflammatory and 
antitumor activity. Its semisolid preparation such as skin cream shows good 
homogeneity and spreadibility. It has prominent property for the sustained release 
drug system with most of the drug and dosage form.   
 [Alaghusundram., et al.,2009] reported microspheres  not only for 
prolonged release, but also for targeting of anticancer drugs to the tumour. In 
future by combining various other strategies, Microspheres will find the central 
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place in novel drug delivery, particularly in diseased cell sorting, diagnostics, gene 
& genetic materials, safe, targeted and effective in-vivo.    
 [Amal H. et al.,2009]  formulated and evaluated captopril Sustained 
release microparticles.using acetate propionate and employing the solvent 
evaporation technique .it decreases the side effects.microparticles containing 
different dug and polymer ratio. 
 [Naikwade S et al.,2009] studied the pulmonary delivery of budesonide 
microparticles formulation and in vitro determination by spray drying. Prepared 
Microparticles were spherical in shape and they are characterized by smooth 
surface with low-density particles. Formulations shown extended in vitro drug 
release up to 4 hours thus use of microparticles possibility offers sustained release 
profile along with increase delivery of drug to the pulmonary tract. 
 [Roy S et al.,2009] prepared mefenamic acid microspheres by cross 
linking chitosan with gluteraldehyde. The invitro release pattern was found to 
follow zero order release as the dissolution exponent come nearer to 1.   
 [A. Dalmoro et al.,2009] prepared enteric microparticles for controlled and 
made drug delivery applications through different ways of microencapsulation 
(namely single emulsions: water in oil-W/O; oil in water-O/W; or double emulsions: 
water-in oil-in water-W/O/W) and their impact on final properties of the product. 
Microcapsules or microsphers can be designed to progressively release active 
ingredients. A coating may also be given to open in specific areas of body “smart 
polymers” which are perfect candidates for advancing self-regulated delivery 
systems. 
 [Ravi Kumar Reddy J. et al.,2009] investigated the delayed release 
microparticles prepared from different polymers by emulsion-solvent evaporation 
method and examined the physic-chemical characters. The mechanism of drug 
release was set up to be erosion as it was caused by (1-Mt/M) 1/3 versus time 
plots. Relative drug release study allow that the formulated product have more 
sustained effect than the marketed product. 
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 [Vinay mishara et al.,2008] prepared and evaluated matrix microspheres 
system for simultaneous and sustained release of Candesartan cilexetil and 
captopril for the management of nephritic syndrome, Ethyl cellulose was used as a 
retardant polymer  decrease of side effect, increase of bioavailability and 
therapeutic action of both combination drugs.   
[KBR chowdary, Dana.,2008] reported that the study is to evaluate ethyl 
cellulose as a coat for controlled release microcapsules of diclofenac.. Ethyl 
cellulose coated microcapsules were prepared by an emulsion-solvent evaporation 
method employing different proportions of core and coat and the microcapsules 
were evaluated for size, drug content and microencapsulation efficiency. 
 [Rajashree hirlekar et al.,2008]  developed muco-adhesive drug delivery 
system of Metoprolol tartarate using various polymer like sodium carboxy methyl 
cellulose and natural polymers like gum karaya, xanthum gum and locust bean 
gum. The formulation containing xanthum gum and locust bean gum in 2:1 ratio 
exhibited complete drug release in 45 minutes.    
 [Lu et a.,2008] formulated a tumor-Penetrating microparticles for 
intraperitoneal therapy of Ovarian Cancer using PLG copolymers. These tumor-
penetrating microparticles were prepared by Emulsion–solvent evaporation 
method. The present study provided several findings that may be applied to 
improving intraperitoneal therapy. 
 [Dr.lakshmanu prabu, shirwaikar.AR et al, 2007] prepared the sustained 
release Aceclofenac microspheres by using rosin as an encapsulating polymer. 
The release rate of drug from the microspheres could be properly controlled for 
about 24h. Appropriate variation in the proportions of drug; polymer and stabilizer 
can lead to a product with the desired controlled release features. 
 [Juergen Siepmann et al.,2006] envisaged that microparticles offer an 
effectual defence of the encapsulated active agent against (e.g. enzymatic) 
degradation, (ii) the chance to precise control the release rate of  the incorporated 
drug above periods of hours to months, and (iii) an easy administration.  
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 [Kevin et al.,2006] emphasized that controlled release drug delivery 
systems are being evolved to address many of the difficulties connect with 
conventional methods of administration. Controlled release drug delivery utilize 
devices such as polymer-based disks, rods, pellets, or microparticles that 
incorporate drug and release it at controlled rates for comparatively long periods of 
time.  
[El-Kamel et al., 2001] prepared floating microparticles of ketoprofen, by 
emulsion solvent diffusion technique. Four different ratios of Eudragit S 100 with 
Eudragit RL were used. The formulation containing 1:1 ratio of the 2 above-
mentioned polymers exhibited high percentage of floating particles in all the 
examined media as evidenced by the percentage of particles floated at different 
time intervals. This can be attributed to the low bulk density, high packing velocity, 
and high packing factor.  
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AIM OF WORK 
             Sitagliptin phosphate is an insulin-sensitizing anti-diabetic drug. It was 
chosen as a model drug since it has a half-life (8-14 h) and bioavailability 87%. It 
belongs to BCS Class III drug(high solubility and low permeability).  Low 
permeability leads to potential problem of poor bioavailability and bioequivalence 
of drug dosage form.  Furthermore, micronized sitagliptin phosphate has shown 
better absorption than nonmicronized form.  Hence, the absorption of drug can be 
enhanced using transdermal microsphere gel technique. 
Sitagliptin phosphate is a dipeptidyl peptidase 4-(DPP-4) inhibitor with 
glucose control capabilities that was effectively used for treating diabetes in the 
past.  However, the oral administration of this drug caused such severe side 
effects that it was removed from the market. 
Sitagliptin is an ideal candidate in considering transdermal diabetic drug 
transport treatment due to its ability to effectively treat diabetes and small overall 
size.  Past studies have concluded that sitagliptin does not cause hypoglycaemia, 
and it requires a low effective concentration in the body.  The minimum effective 
concentration of sitagliptin required in the blood is  100 nM.   When sitagliptin is 
taken orally, there are many negative side effects that have been reported which 
include severe digestive discomfort, general pain, upper respiratory tract 
infections, and headache.  However, by delivering sitagliptin transdermally, there 
is potential for these side effects to be circumvented through avoiding digestive 
overload. 
Type II diabetes is caused by insulin resistance and occurs when the 
pancreas produces insulin, though the body does not appropriately react to the 
protein.  Type II diabetes increases one’s risk for many other health problems such 
as heart and blood vessel diseases, kidney damage, vision degeneration, nerve 
damage, and foot damage.  Patients with type 2 diabetes continuously alternate 
between a hyperglycaemic state, which refers to high blood glucose and low blood 
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glucose levels, respectively.  It is imperative for these patients to monitor their 
blood glucose levels in order to remain in good health.   
Oral drug delivery and liquid injections are currently the two most common 
forms of diabetes treatment.  However, both methods implicitly present limitaitons.  
Patients who take oral anti-diabetic medications typically require high dosages in 
order for sufficient efficacy due to low bioavailability in drug of this class.  Patients 
also tend to experience negative side effects, such as vomiting and digestive pain 
from taking high dosage oral anti-diabetic medications.  Patients who take 
hypodermic insulin injections are required to inject themselves with insulin up to 
three times a day; this method is very painful and inconvenient for patients who 
are dependant on this life-saving protein.  A feasible treatment option for diabetes 
lays in transdermal drug delivery approaches.  It has been shown that the skin is a 
barrier that can be exploited for drugs to enter the body, so transdermal patch or 
cream formulation has potential for development as an alternative to the typical 
diabetes treatment. 
Furthermore, the use of transdermal patches can provide sustained drug 
release over hours, and even days.  This novel methodology for diabetes 
treatment would have the ability to enable patients to lead quality lives without the 
pain from the numerous hypodermic insulin injections or the negative side effects 
caused by oral anti-diabetic medications.  However, this delivery method 
possesses limitations of its own, such as the necessity of selecting a drug small 
enough to facilitate transdermal diffusion.   
Microspheres have been widely accepted as a means to achieve sustained 
release drug delivery system.  The microspheres requires a polymeric substance 
as a carrier and a core material.  Among the various methods developed for 
formulation of microspheres, the non-aqueous solvent evaporation method has 
gained much attention due to its ease of fabrication without compromising the 
activity of drug.   
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     Eudragit RS 100 is referred as a ammoniomethacrylate copolymers, with the 
former having 5%functional quaternary ammonium groups and the latter having 
10% functional quaternary ammonium groups.  Eudragit RS 100 is a water-
insoluble polymer that is widely used as a wall material for sustained release 
microspheres due to its biocompatibility, good stability, easy fabrication and low 
cost. 
      HPMC is a non-ionic, swellable polymer.  Hydrophyllic polymer gel matrix 
systems are widely used in sustained drug delivery to obtain a desirable drug 
release profile and cost effectiveness because of their flexibility.  The hydration 
rate of HPMC increases with increase in the hydroxyl propy content.   
      The use of natural polymers is preferred due to their proven biocompatibility 
and safety.  In this respect, chitosan, a cationic polymer, has attracted particular 
attention.  It is biocompatible and bioadhesive at physiological pH ande possesses 
OH and NH2 groups that can give rise to hydrogen bonding.  It is a high molecular 
weight polysaccharide, compromising of glucosamine and N-acetyl glucosamine 
obtained by deacetylation of chitin.  Because of its low production cost, non-toxic 
nature, chitosan has found application in multiparticulate drug delivery. 
Carbopol is a polymer consisting of acrylic acid cross-linked with either 
polyalkenyl ether or divinyl glycol.  It readily absorbs water, gets hydrated and 
swell.  In addition to hydrophilic nature, cross-linked structure and insolubility in 
water, due to the high proportion of the carboxy groups present, carbomer solution 
is known to be acidic.  It is also low viscosity but when neutralized with 
triethanolamine, it is converted to high viscous gels.  The adhesive properties of 
carbomer are exploited to develop bioadhesive gels and drug delivery systems for 
sustained and localized drug delivery. 
Transdermal drug administration generally refers to topical applications of 
agents to healthy intact skin either for localized treatment of tissues underline the 
skin of for systemic therapy.  For transdermal product, the goal of dosage design 
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is to maximize the flux through the skin into the systemic circulation and 
simultaneously minimize the retention and metabolism of the drug in the skin. 
Transdermal drug delivery has main advantage over the oral route of 
administration such as improving patient compliance in long term therapy, by-
passing first pass metabolism, sustaining drug delivery, maintaining a constant 
and prolonged drug level in plasma, minimizing the inter and intra-patient 
variability, and making it possible to interrupt or terminate when necessary. 
Transdermal route will eliminate the side effects associated with oral 
administration of sitagliptin phosphate.  The aim of this present study was to 
formulate and evaluate sustained release microsphere gel loaded sitagliptin 
phosphate in order to maintain a sustained drug concentration in serum for longer 
period of time, which may result in enhanced absorption and thereby improved 
bioavailability. 
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PLAN OF WORK 
 
1. STANDARD CURVE FO SITAGLIPTIN PHOSPHATE 
 Preparation of calibration curve 
 Estimation of absorption maximum 
 Preparation of standard curve 
 
2. PREFORMULATION STUDIES 
 Fourier transform infra-red spectroscopic 
 Differential Scanning Calorimetric studies 
 
3. FORMULATION OF SITAGLIPTIN PHOSPHATE MICROSPHERES 
  The microspheres are prepared by non-aqueous solvent evaporation method. 
 
4. CHARACTERIZATION OF SITAGLIPTIN PHOSPHATE MICROSPHERES 
 Determination of drug content 
 Determination of mean particle size 
 Scanning Electron Microscopic 
 Determination of percentage yield 
 Determination of encapsulation efficiency 
 In-vitro dissolution studies 
 
5. SELECTION OF BEST FORMULATION 
6. PREPARATION  OF GEL LOADED SITAGLIPTIN MICROSPHERES 
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7. CHARACTERIZATIION OF GEL LOADED SITAGLIPTIN MICROSPHERES 
 Deternmination of pH  
 Determination of gel strength 
 Determination of spreadability 
 Determination of  drug content 
8. COMPARATIVE IN-VITRO STUDIES 
9. STABILITY STUDIES 
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MATERIALS AND EQUIPMENTS 
 
LIST OF MATERIALS  
 
Table- 2. List of Materials Used 
Materials Manufacturer 
Sitagliptin phosphate Pure chem Pvt. Ltd. Gujarat 
Eudragit RS 100 Universal Scientific Appliances, Madurai. 
HPMC E15 Universal Scientific Appliances, Madurai. 
Chitosan Universal Scientific Appliances, Madurai. 
Tween 80 Universal Scientific Appliances, Madurai. 
Carbopol 934 Universal Scientific Appliances, Madurai. 
Triethanolamine Universal Scientific Appliances, Madurai. 
Acetone Universal Scientific Appliances, Madurai. 
Liquid paraffin Universal Scientific Appliances, Madurai. 
Petroleum ether Universal Scientific Appliances, Madurai. 
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EQUIPMENTS USED 
TABLE-3 
EQUIPMENTS NAME MANUFACTURERS 
Electronic weighing balance A & D company, Japan. 
UV – Visbile spectrophotometer Shimadzu corporation, Japan 
Infrared Spectroscopy Spectrum RX-1, Perkin Elmer, 
German 
Differential Scanning  Calorimetry DSC Q 200, USA 
Scanning Electron Microscopy Hitachi X 650, Tokyo,Japan 
Optical microscope Towa Optics, India 
Mechanical  stirrer Remi, India 
Magnetic stirrer Remi, India 
Environmental stability testing 
chamber 
In Labs equipment(Madras) 
Pvt.Ltd. 
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DRUG PROFILE 
 
SITAGLIPTIN PHOSPHATE: 
Structure: 
                        
Chemical Name:  
4-Oxo-4- (3-(trifluoromethyl)   5,6 dihydro (1,2,4) triazolo [4,3a] 
pyrazin-7 (8H) -yl) -1- (2,4,5-trifluorophenyl) butan-2 amine phosphate 
Empirical Formula : 
      C16H15F6N5O.H3PO4 
Molecular Weight :  
      505.31gm/mol 
Description :  
      white to off-white crystalline powder 
Melting Point:  
     198 – 202oC 
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Category: 
      Hypoglycemic agent DPP-4 inhibitor. 
Brands:  
     Januvia, Janumet 
Dose  :  
     25 to 100 mg daily, in divided doses or once daily. 
PKa: 
      12.4 
pH: 
       pH of 1% aqueous solution of drugs is 6.68 
Solubility: 
       Freely soluble in water, slightly soluble in ethanol (95%) practically insoluble in 
acetone, chloroform, dichloromethane  and ether. 
 BCS Classification: 
     It is a BCS class III (high solubility, low permeability)/borderline class I (high 
solubility, high permeability) drug        
Sitagliptin Phosphate Pharmacokinetics 
Absorption 
Absolute bioavailability 87%. 
Rapidly absorbed following oral administration; at steady state (within 3 
days of therapy initiation), peak plasma concentrations generally attained ≤3 hours 
following administration of recommended doses. 
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Onset 
Reduction in postprandial plasma glucose excursion: Approximately 60 
minutes. 
Duration 
Approximately 80% inhibition of DPP-4 activity persists for 12 or 24 hours 
following administration of ≥50 or ≥100 mg, respectively, of sitagliptin. 
Food 
Food does not appear to affect absorption.1 
Special Populations 
Renal impairment results in increased plasma AUC.Removed modestly by 
hemodialysis; time to peak plasma drug concentration increased in a limited 
number of patients with end-stage renal disease requiring hemodialysis. 
Moderate hepatic impairment results in increased peak plasma 
concentrations and AUC; not considered clinically important. 
In geriatric patients, modest increases in plasma concentrations compared 
with younger adults. 
Distribution 
Distributed into milk in rats; not known whether distributed into human milk. 
Plasma Protein Binding 
38%. 
Metabolism 
Metabolized to a limited extent by CYP isoenzymes 3A4 and 2C8 to 
inactive metabolites. 
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Elimination Route 
Eliminated principally by kidneys via active tubular secretion.   Excreted in 
urine (87%) mainly as unchanged drug and in feces (13%). 
Half-life 
12.4 hours. 
Special Populations 
Renal impairment results in increased terminal elimination half-life. 
Storage 
20–25°C (may be exposed to 15–30°C). 
Actions 
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 Inhibits DPP-4, an enzyme that inactivates incretin hormones glucagon-like 
peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). 
 Inhibits DPP-4 selectively with no effect on DPP-8 or DDP-9 in vitro at 
concentrations approximating those from therapeutic dosage. 
 Increases circulating concentrations of GIP and GLP-1 in a glucose-
dependent manner.  Coadministration of sitagliptin and metformin has an 
additive effect on active GLP-1 concentrations. 
 GIP and GLP-1 stimulate insulin synthesis and release from pancreatic β-
cells in a glucose-dependent manner (i.e., when glucose concentrations are 
normal or elevated) by intracellular signaling pathways involving cyclic 3′,5′-
adenosine monophosphate (cAMP). 
 GLP-1 also decreases glucagon secretion from pancreatic α-cells in a 
glucose-dependent manner, leading to reduced hepatic glucose production. 
 Lowers fasting plasma glucose concentrations and reduces glucose 
excursions following glucose load or meal in patients with type 2 diabetes 
mellitus. 
 Sitagliptin usually not associated with hypoglycemia or substantial changes 
in body weight. 
Cautions for Sitagliptin Phosphate 
Contraindications 
 Known serious hypersensitivity (e.g., anaphylaxis, angioedema) to 
sitagliptin or any ingredient in formulation. 
Warnings/Precautions: 
 Pancreatitis and Pancreatic Precancerous Changes 
 Worsening of Renal Function 
 Severe Arthralgia 
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 Sensitivity Reactions 
 Loss of Glycemic Control 
 Macrovascular Outcomes 
Pregnancy 
Category B. 
Lactation 
Distributed into milk in rats; not known whether distributed into human milk. 
Pediatric Use 
Safety and efficacy of sitagliptin alone or in fixed combination with 
metformin not established in children <18 years of age. 
Geriatric Use 
No substantial differences in safety and efficacy relative to younger adults, 
but increased sensitivity cannot be ruled out. 
Substantially eliminated by kidneys; assess renal function prior to initiation 
of therapy and periodically thereafter because geriatric patients more likely to have 
decreased renal function. 
Renal Impairment 
Substantially eliminated by kidneys; assess renal function prior to initiation 
of therapy and periodically thereafter. 
Common Adverse Effects 
Sitagliptin monotherapy or add-on therapy with metformin and/or a 
thiazolidinedione or glimepiride: Nasopharyngitis, upper respiratory tract 
infection, peripheral edema, headache. 
Interactions for Sitagliptin Phosphate 
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Metabolized to a limited extent by CYP isoenzymes 3A4 and 2C8 to 
inactive metabolites. 
Drugs Metabolized by Hepatic Microsomal Enzymes 
Does not inhibit CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4 
in vitro or induce CYP3A4.  Pharmacokinetic interactions with drugs metabolized 
by these isoenzymes unlikely. 
Inhibitors of P-glycoprotein Transport System 
Substrate of p-glycoprotein transport system.  Potential pharmacokinetic 
interaction (increased absorption and renal clearance of sitagliptin) with   
p-glycoprotein inhibitors. 
Clinically important pharmacokinetic interactions with p-glycoprotein 
inhibitors unlikely. Does not appear to inhibit p-glycoprotein transport system. 
Drugs Secreted by Renal Tubular Cationic Transport 
Substrate of organic anion transport system; pharmacokinetic interaction 
unlikely with substrates of organic cationic transport system. 
Protein-bound Drugs 
Pharmacokinetic interaction unlikely. 
There are several therapeutic options for the treatment of type 2 diabetes, which 
can include lifestyle modification with diet and exercise, as well as drug therapy.  
They are, 
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TABLE-4 
Insulin 
Sensitizers 
Biguanides (Metformin, Buformin, Phenformin) 
 TZDs/"Glitazones" (PPAR) (Pioglitazone, Rivoglitazone, 
Rosiglitazone, Troglitazone)  
Dual PPAR agonist (Aleglitazar, Muraglitazar, Tesaglitazar) 
Insulin 
Secretagogues 
K+ ATP, Sulfonylureas (1st generation: Acetohexamide, 
Carbutamide, Chlorpropamide, Metahexamide, Tolbutamide, 
Tolazamide) 
 K+ ATP, Sulfonylureas (2nd generation: 
Glibenclamide(Glyburide), Glibornuride, Glipizide, 
Gliquidone, Glisoxepide, Glyclopyramide, Glimepiride, 
Gliclazide) 
 K+ ATP, Meglitinides/"glinides" (Nateglinide, Repaglinide, 
Mitiglinide) GLP-1 agonists (Exenatide, Liraglutide, 
Taspoglutide, Albiglutide, Lixisenatide)  
DPP-4 inhibitors (Alogliptin, Gemigliptin, Linagliptin, 
Saxagliptin, Sitagliptin, Vildagliptin)  
Analogs/Other 
Insulins 
Fast-acting (Insulin Lispro, Insulin aspart, Insulin Glulisine) 
 Short-acting (Regular Insulin) 
 Long-acting (Insulin Glargine, Insulin Detemir, NPH Insulin) 
 Ultra-long-acting (Insulin Degludec) 
 Inhalable (Exubera) 
AlphaGlucosidase 
Inhibitors 
Acarbose, Miglitol, Voglibose 
Amylin Analog Pramlintide 
SGLT2 Inhibitors 
Canagliflozin, Dapagliflozin, Empagliflozin, Remogliflozin, 
Sergliflozin, Tofogliflozin 
Other Benfluorex, Tolrestat 
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EXCIPIENTS PROFILE 
HYDROXYPROPYL METHYLCELLULOSE 
 
Description   : Odourless, tasteless, white or creamy-white coloured  
      fibrous or granular powder.  
Molecular weight  : Approximately 10,000 - 1,500,000. 
 Structural formula :   
  
Applications   : Primarily in the oral products hydroxypropyl  
    methylcellulose was used as a tablet binder, extended  
    release tablet matrix, suspending and thickening agent  
               particularly in ophthalmic preparations. It is widely  
               used in cosmetics and food products and also used as  
    a wetting agent for hard contact lenses and as an  
    adhesive in plastic bandages. 
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Acidity / Alkalinity   : pH = 5.5 - 8.0 for a 1% w/w aqueous solution.  
Density (tapped)   : 0.50 - 0.70 g / cm3 for pharmacoat.  
Melting point   : Browns at 190-200oC. Glass Transition Temperature  
      is  170 - 180oC. 
Solubility     : Soluble in cold water and practically insoluble in  
   ethanol (95%), ether and chloroform. But soluble in  
    mixtures of methanol and dichloromethane and  
    mixtures of ethanol and dichloromethane.  
Stability     : Its powder is a stable material although it is  
    hygroscopic after drying. 
Incompatibilities   : Incompatible with some oxidizing agents and will not  
   complex with metallic salts and ionic organics.  
Safety     : Extensively used in cosmetics, food products and  
    widely used as an excipient in oral and topical  
    formulations. 
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CARBOPOL 
Chemical name   : Carboxy polymethelene  
Empirical formula   : (C3H4O2) x (-C3H5-sucrose) y  
Grades     : 907, 910, 934, 934P, 940, 941, 971P, 974P, 980.  
 
Structural formula  : 
                                             
Description    : White, fluffy, acidic, hygroscopic powder with a  
          slight characteristic odour.  
Molecular weight   : 1 x 106 to 4 x 106. 
Density     : Bulk: 5 g / cm3.  
  Tapped: 1.4 g / cm3.  
Viscosity     : 29,400 to 39,400 cps at 2 oC (0.5% neutralized  
   aqueous solution).  
pH      : 2.5 - 3.0 (1% aqueous solution) 
Solubility     : Soluble in water, alcohol and glycerin.  
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Stability     : It is relatively unaffected by temperature variations,  
   not subjected to hydrolysis or oxidation and is  
   resistant to bacterial growth. 
Applications   : It is excellent thickening, emulsifying, suspending  
   and gelling agent. It is used as a tablet binder in  
                                    sustained release formulations affording zero- to near  
    zero order release. It is used as the bioadhesive  
                                    component in mucoadhesive ointments, gels and  
    tablets.  
Safety     : No primary irritation or any evidence of allergic  
   reactions has been observed in human beings  
   following topical application.   
Incompatibility   :It is observed with cationic polymers, phenols,  
    resorcinol and high concentration of electrolytes. 
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                      CHITOSAN 
 
Chemical name    : Poly-b-(1,4)-2-Amino-2-deoxy-D-glucose 
 Description    : Odourless, white or creamy-white powder or  
       flakes. 
  Structural formula   : 
       
Molecular formula   : C6H11NO4n 
Molecular weight   : 10,000 - 1,000,000 
 Solubility     : Easily soluble in water. 
 Moisture content   : 10%  
Ash content    : 2.0%  
Applications   : Excellent film forming agent, additives, cosmetics  
    and good bacterial inhibitor. Also used for the  
    preservation of fruits and vegetables. It is widely  
    applied for improving immunity, activating cells,  
    preventing cancer, decreasing blood fat and blood  
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    pressure, adjusting blood sugar, fighting against  
    ageing and adjusting organism environment. 
Incompatibilities   : Incompatible with strong oxidizing agents.  
Stability     : Chitosan powder is a stable material at room  
    temperature, although it is hygroscopic after drying.   
Safety     : Widely for use as an excipient in oral, cosmetics and  
     other pharmaceutical formulations. Generally regarded  
     as a nontoxic and nonirritant material. It is  
     biocompatible with both healthy and infected skin  
     and shown to be biodegradable. 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER VIII                                                      EXCIPIENTS PROFILE 
 
COLLEGE OF PHARMACY, MADURAI MEDICAL COLLEGE. Page 75 
 
EUDRAGIT- RS100 
Molecular weight   : Is approximately 135,000. 
Description    : White powders with a faint characteristic odour. 
Structural formula  : 
                                 
Solubility     : Dissolves in methanol, ethanol, aqueous isopropyl  
   alcohol and acetone. Practically insoluble in ethyl  
   acetate, methylene chloride, petroleum ether and  
   water 
Particle size   : At least 95%, less than 0.25 mm. 
Film formation   : When poured onto a glass plate, a clear film forms  
    upon evaporation of the solvent.  
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Applications   : Polymethacrylates are primarily used in oral capsule  
     and tablet formulations as film coating agents.  
     Depending on the type of polymer used, films of  
     different solubility characteristics can be produced.  
     Eudragit acrylic resins exhibit a broad spectrum of  
     physicochemical properties and are used in a variety  
     of pharmaceutical applications, such as film coating  
     of oral formulations and preparation of controlled 
     release drug systems. 
Stability     : Minimum stability dates are given on the product  
      labels and batch-related certificates of analysis. 
Storage     : Protect from warm temperatures and against  
      moisture. 
Safety     : Polymethacrylate co-polymers are widely used as  
     film coating materials in oral pharmaceutical  
     formulations. They are also used to a lesser extent in  
     topical formulations and are generally regard as non 
             toxic and non-irritant materials.   
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EXPERIMENTAL PROTOCOL 
Preformulation study:   
Preformulation testing is the first step in the rational development of dosage 
forms of a drug substance. It can be defined as an investigation of physical and 
chemical properties of a drug substance alone and when combined with 
excipients. The overall objective of pre-formulation testing is to generate 
information useful to the formulator in developing stable and bio available dosage 
forms that can be man produced.   
The following preformulation studies are carried out:   
 Description  
 Finding the absorption maxima  
 Standard curve   
 Infra-red spectroscopy studies (compatibility studies) 
 Differential Scanning Calorimetry    
Description   
            About 1g of sample is taken in a dry petridish and the sample is observed 
for compliance against the specification.     
Identification of the drug: Finding the absorption maxima (λ max)   
The absorption maxima were found for drug identification. Ultraviolet Visible 
spectrophotometry has been used to obtain specific information on the 
chromophoric part of the molecules. Organic molecules in solutions when exposed 
to light in the visible/Ultraviolet region of the spectrum absorb light of particular 
wavelength depending on the type of electronic transition associated with the 
absorption.   
        The various batches of the microspheres were subjected for drug content 
analysis. Accurately weighed microsphere samples were mechanically powdered. 
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The powdered microspheres were dissolved in adequate quantity of phosphate 
buffer PH 7.2 then filter. The UV absorbance of the filtrate was measured using a 
UV spectrometer at 267nm.   
Fourier transform infrared (FTIR) spectral analysis   
FT-IR is used to identify the functional groups in the molecule. The drug is 
mixed with KBr and pellet is formed. Each KBr disk was scanned at 4 mm/s at a 
resolution of 2 cm over a wave number region of 400 to 4,500 cm−1. The 
characteristic peaks were recorded. The results are shown in the following figure. 
and table.   
Drug-Excipient Compatibility studies by FT-IR   
Fourier infrared spectroscopy (FT-IR) analysis was performed for the pure 
drug and physical admixtures (Polymers, excipients) individually and then the drug 
and physical admixtures are mixed together and FT-IR is taken to find out that 
there is no interaction between drug, polymers and the excipients.  The results are 
shown in the following figure.and table.  
Differential Scanning Calorimetry(DSC): 
Differential scanning calorimetry or DSC is a thermo analytical technique in 
which difference in the amount of heat required to increase the temperature of a 
sample and reference as a function of temperature.  Both the sample and 
reference mentioned at nearly sample temperature throughout the experiment. 
Mehtod: 
Accurately weighed sitagliptin phosphate and formulations were analyzed 
using an automatic thermal analyzer by using an automatic thermal analyzer 
system (DSC60 Shimadzu Corporation Japan).  Sealed and perforated aluminium 
pans were used in the experiments for all the samples.  Temperature calibrations 
were performed using indium as a reference.  The entire sample were run at a 
scanning rate of 10oc/min from 50 oc-300 oc. 
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Standard Curves For Sitagliptin Phosphate :  
Preparation of O.1N HCL:(Indian Pharmacopoeia 2010) 
8.5 ml of Hydrochloric acid was dissolved in 1000ml of distilled water. 
Preparation of Phosphate Buffer pH 7.2: 
A known volume of 0.2M potassium dihydorgen phosphate is placed in a 
200ml volumetric flask.  22.4ml of 0.2M sodium hydroxide is added and make up 
to the volume with distilled water. 
0.2M Pottasium Dihydrogen Phosphate: 
A known quantity(27.218g) of potassium dihydorgen phosphate is dissolved 
and diluted to1000ml with water 
0.2M Sodium Hydroxide: 
A known quantity (8g) of sodium hydroxide is dissolved and make up to        
1000 ml with water. 
Estimation of absorption maximum: (λ max)   
The sitagliptin phosphate drug solutions (5,10,15,20 and 25µg/ml) were 
taken in a standard cuvette and scanned in the range of 200-400nm by using UV-
Spectrophotometer. The absorbance of each sample was measured at 267nm. 
The standard curve is plotted against absorbance and concentration of the 
sample. Similarly, the procedure can be repeated for phosphate buffer pH 7.2. and 
for 0.1N HCL.. 
FORMULATION OF SITAGLIPTIN PHOSPHATE MICROSPHERES: 
The microspheres containing the anti-diabetic drug, sitagliptin phosphate, 
as the core material were prepared by a non-aqueous solvent evaporation 
method. (Garud and Garud.,2012) 
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The drug and the plymers were mixed with acetone at various ratos. The 
slurry was introduced into 100ml of liquid paraffin while stirring with a mechanical 
stirrer equipped with a three-blade propeller at room temperature.  The solution 
was stirred for 4 hours to allow the solvent to evaporate and the microspheres 
were collected by filtration by Whatman filter paper no. 1.  The microspheres were 
washed repeatedly with petroleum ether(40oc-60oc) until free from oil.  The 
microspheres were collected and dried for 3hours at room temperature stored in a 
dessicator over fused calcium chloride. 
CHARACTERIZATION OF SITAGLIPTIN MICROSPHERES: 
Determination of mean particle size: 
The particle size was measured using an optical microscope, and the mean 
particle size was calculated by measuring 300 particles with the help of a 
calibrated ocular micrometer. A small amount of dry microspheres was suspended 
in liquid paraffin (10 ml). A small drop of suspension thus obtained was placed on 
a clean glass slide. The slide containing microspheres was mounted on the stage 
of the microscope and diameter of at least 300 particles was measured using a 
calibrated optical micrometer. 
Scanning Electron Microscopy:    
The purpose of the Scanning Electron Microscopy study was to obtain a 
topographical characterization of micropsheres. The micropsheres were mounted 
on brass stubs using double-sided adhesive tape. Scanning electron microscopy 
photographs were taken with a scanning electron microscope (JSM-5610LV, Joel 
Ltd, Tokyo, Japan) at the required magnification at room temperature. The working 
distance of 39 mm was maintained, and the acceleration voltage used was 15 kV, 
with the secondary electron image as a detector.  
Yield of Microspheres   
The prepared Microspheres were collected and weighed. The actual weight 
of obtained Microspheres divided by the total amount of all non-volatile material 
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that was used for the preparation of the Microspheres multiplied by 100 gives the 
% yield of Microspheres.  
This was calculated by the use of following formula.  
 % yield= (Actual weight of the product / Total weight of excipients and drug) 
× 100   
Determination of Drug Content and Encapsulation Efficiency    
100 mg of accurately weight microspheres were suspended in a phosphate 
buffer pH 7.2 upto 24 hours. Next day, the sample was shaken using mechanical 
shaker for few hours. Then it was filtered and from the filtrate, few ml of aliquot 
was taken and made the suitable dilutions and analyzed for the drug content at 
267 nm by spectrophotometry. The % of Encapsulation Efficiency was calculated. 
Taking into the consideration the dilution factor and the amount of micro beads 
takes, the amount of drug encapsulation per unit weight of micro beads were 
calculated.  The drug encapsulation efficiency was calculated using for the formula   
Encapsulation efficiency=practical drug content/theoretical drug content*100 
Evaluation of in vitro release by static method: 
Microspheres, equivalent to 25 mg of sitagliptin phosphate, were accurately 
weighed and transferred to beaker containing 100 ml phosphate buffer (pH 7.2). 
The flask was kept in a magnetic stirrer at 37oc, 1 ml samples  withdrawn at 
regular intervals and, after suitable dilution, the amount of drug released was 
determined using a spectrophotometer at 267 nm. Following each sample 
withdrawal, 1 ml of phosphate buffer was added to the release medium to 
replenish it. The microspheres were allowed to settle down and clear supernatant 
medium withdrawn for drug analysis. Samples were collected for every 1 hour and 
the study was carried over for 12 hours. The sample was filtered and the 
microspheres collected were transferred to the dissolution flask. (Karthikeyan K., 
et al., 2012)   
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Kinetics of drug Release:  
Several theories and kinetic models describe the dissolution of drug from 
immediate release and modified release dosage forms. There are several models 
to represent the drug dissolution profiles where f (t) is a function of time related to 
the amount of drug dissolved from the pharmaceutical dosage form.  
                The quantitative interpretation of the values obtained in the dissolution 
assay is facilitated by the usage of a generic equation that mathematically 
translates the dissolution curve function of some parameters related with the 
pharmaceutical dosage forms. Drug dissolution from solid dosage forms has been 
described by kinetic models in which the dissolved amount of drug (Q) is a 
function of the test time‘t’ or Q(t). Some analytical definitions of the Q(t) function 
are commonly used, such as zero order, first order, Higuchi, Korsmeyer-Peppas, 
Hixson-Crowell models, Weibull models. These models are used to characterize 
drug dissolution/release profiles.   
(i) Zero Order Kinetics  
This model represents an ideal release profile in order to achieve the 
pharmacological prolonged action. Zero order release constitutes drug release 
from the dosage form that is independent of the amount of drug in the delivery 
system (that is, a constant release rate). The following equation is used to express 
the model:   
Qt = Qo + Kot   
Where,  
Qt is the amount of drug dissolved in time t  
Qo is the initial amount of drug in the solution                                     
 Ko is the zero order release constant   
For practical purposes the equation is rearranged:  
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Percent drug released = Kt   
This is applicable to dosage forms like transdermal systems, coated dosage 
forms, osmotic systems as well as matrix tablets with low soluble drugs.   
(ii) First Order Kinetics   
First order release constitutes drug release in a way that is proportional to 
the amount of drug remaining in its interior; in such a way that amount of drug 
released by unit time diminish. The following equation is used to express the 
model:   
log Qt = log Qo + Kt/2.303   
Where,  
Qt is the amount of drug dissolved in time t   
Qo is the initial amount of drug in the solution                          
 K is the first order release constant   
For practical purposes the equation is rearranged:   
Log % of drug unreleased = Kt/2.303   
This model is applicable to dosage forms such as those containing water 
soluble drugs in porous matrices.   
 (iii) Higuchi Model   
Higuchi describes drug release as a diffusion process based in Fick’s 
law,square root dependent. The following equation is used to express the model: 
  Qt = Kht1/2   
Where,  
 Qt is the amount of drug dissolved in time t 
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 Kh is the first order release constant  
For practical purposes the equation is rearranged:  
 Percent drug released = Kt1/2   
This model is applicable to systems with drug dispersed in uniform 
swellable polymer matrix as in case of matrix tablets with water soluble drug.   
(iv) Peppas-Korsmeyer Model:   
This model is widely used when the release mechanism is not well known 
or when more than one type of release phenomenon could be involved   
The following equation is used to express the model   
           Qt/Q∞ = Ktn  
Where,    
Qt is the amount of drug dissolved in time t     
Q∞ is the amount of drug dissolved in infinite time 
n is the release exponent indicative of drug release mechanism K is the 
kinetic constant   
For practical purposes the equation is rearranged:   
Log percent drug released = log k +n log t 
Peppas used n value in order to characterize different release mechanism 
concluding for values of n = 0.5 for Fickian diffusion and values of n, between 0.5 
to 1.0 for anomalous transport (corresponds to diffusion, erosion and swelling 
mechanism or mixed order kinetics) and higher values of n, n=1 or n>1 for case-II 
transport (corresponds to erosion and relaxation of swollen polymer layer).      
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PREPARATION OF GEL: 
Accurately weighed sitagliptin phosphate miccrospheres( drug equivalent) 
was added to 15ml of water in a beaker and stirred well, 400 mg of carbopol was 
added to that microspheres dispersion, while stirring at 250 rpm, to obtain a 
homogenous mixture.  Stirring was continued until a lump free suspension was 
obtained.  Thereafter, 0.33ml of triethanolamine was added to produce  a gel.             
(Karthikeyan K., et al., 2012)  
Evaluation of microspheres-loaded gel: 
Determination of pH:  
Determination of pH was done by Indosati Digital pH meter pH meter was 
calibrated before use using standard buffer solution. 
Gel strength determination: 
A composition of 50 g of microspheres-loaded gel was taken in a 10 ml 
beaker. The weight of 1000 mg for measuring gel strength was allowed to 
penetrate into the gel.  The gel strength, which means the viscosity of the gel, was 
determined by time (seconds) 
 Spreadability  
A sample of 0.5 g of each formulation was pressed between two slides 
(divided into squares of 5 mm sides) and left for about 5 minutes where no more 
spreading was expected. Diameters of spreaded circles were measured in cm and 
were taken as comparative values for spreadability. The results obtained are 
average of three determinations. 
 Drug content: 
About 0.5 g of gel was dissolved in 25 mL  phosphate buffer at pH 7,2. It 
was then filtered after constant stirring and analyzed by UV spectrophotometer 
after suitable dilution at 267 nm. 
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Evaluation of in vitro release by dynamic method: 
Evaluation of in vitro release studies of sitagliptin phosphate carbomer gel 
was carried out at 37oc using phosphate buffer (pH 7.2) as the release medium. A 
glass tube of 10 mm diameter and 100 mm height was taken. One end of the tube 
was closed using an dialysis membrane with the help of adhesive tape while the 
other end was kept open and used as drug reservoir compartment. Gel (1 g) 
containing sitagliptin phosphate was accurately weighed and transferred to the 
glass tube in a vertical position through the open end. The gel was gently pushed 
down to the surface of the dialysis membrane with the help of a stainless steel 
spatula to ensure that all the gel was in contact with the membrane. Phosphate 
buffer (2 ml, pH 7.2) was added to the reservoir compartment to wet the gel. The 
glass tube was placed in a beaker containing 100 ml of phosphate buffer (pH 7.2) 
such that that the dialysis membrane is just immersed in the phosphate buffer 
which acted as the receiving compartment. The receiving compartment was 
magnetically stirred (100 rpm, Remi, India) at 37oc. Samples (1 ml) were 
withdrawn from the receiving compartment at regular 1hour intervals and the 
amount of sitagliptin phosphate released from the gel was determined using a 
spectrophotometer at 267 nm. After each withdrawal of sample, an equal quantity 
of phosphate buffer was added to the receiving compartment to replenish it. 
Samples were collected for every 1 hour and the study was carried over for 12 
hours. (Karthikeyan K., et al., 2012)  
Stability Study    
Accelerated Stability Studies   
Stability   
Stability is officially defined as the time lapse during which the drug product 
retains the same property and characteristics that it possessed at the time of 
manufacture. This process begins at early development phases.   
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Definition Stability of a pharmaceutical preparation can be defined as “the 
capability of a particular formulation (dosage form or drug product) in a specific 
container/closure system to remain within its physical, chemical, microbiological, 
therapeutic and toxicological specifications throughout its shelf life.    
Instability in modern formulation is often undetectable only after 
considerable storage period under normal conditions. To assess the stability of a 
formulated product it is usual to expose it to high stress conditions to enhance 
deterioration and therefore the time required for testing is reduced. Common high 
stress factors are temperature and humidity. This will eliminate unsatisfactory 
formulation.   
Purpose of stability testing:   
 To study of drug decomposition kinetics 
  To develop stable dosage form  
 To establish the shelflife or expiration date for commercially available drug 
product.  
 To ensure the efficacy, safety and quality of active drug substance and 
dosage forms.                                          
Table - 5 Stability Conditions Chart 
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The stability studies of formulation F1 to F15 were carried out at 45° C ± 
2°C 75% ± 5% RH and leakage of the drug from the microspheres were analyzed 
in terms of percentage drug content.   
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RESULTS AND DISCUSSION 
 
PREFROMULATION:  
Description     -       White, Odourless powder. 
STANDARD CURVES FOR SITAGLIPTIN PHOSPHATE: 
The calibration medium pH (7.4) were prepared by using phosphate buffer 
and       0.1 NHCL were as per the I.P procedure(I.P 2010) 
Estimation of absorption maximum (λmax): 
The λmax of sitagliptin phosphate was estimated by scanning the 10µg/ml 
concentration of the drug solution in buffer solution of phosphate buffer pH (7.4) 
and λmax of 267nm in phosphate buffer solution and λmax of 267nm in 0.1N HCL.  
The results were shown in table-5a and table-5b. 
Preparation of Standard curves: 
The standard curves of sitagliptin phosphate prepared by using phosphate 
buffer pH (7.4) and 0.1N HCL.  The linear correlation coefficient was found to be 
0.999605 and sitagliptin obeys the Beer’s law within the concentration range of     
5-25µg/ml. 
IR spectra study: 
From IR spectra of sitagliptin, physical mixture of drug and polymer, and 
Microspheres it can be seen that there is no significant change in IR spectra of 
microspheres i.e., it is nearly same to that of plain compounds. IR Spectra is 
shown in figure-5 a, b, c, d. 
DSC spectra study: 
The DSC thermogram of sitagliptin base exhibited an exothermic peak at 
about 208.76oC corresponding to its melting point. But in thermal analysis, 
sitagliptin-loaded microspheres show peak originating from sitagliptin only slighty 
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difference in peak of temp. From DSC spectra of sitagliptin peak shown, and 
microspheres shown peak at, near to drug peak indicate that there is no significant 
change in DSC spectra of microspheres i.e., it is nearly same to that of plain 
compounds. DSC Spectra is shown in figure 6-a,b. 
Formulation of Sitagliptin Phosphate Microspheres: 
The sitagliptin microspheres were prepared by non-aqueous solvent 
evaporation method.  The microspheres were prepared by using Eudragit rs 100 in 
different ratios. After conducting five trial batches(F1-F5) it was optimized by 
characterization and changing the parameters such as stirring speed, rpm, 
polymer ratios and (F6-F10) batches were prepared along with HPMC E15 and 
(F11-F15) were prepared along with chitosan as a rate retardant polymers.   
Characterization of Sitagliptin Phosphate Microspheres: 
All the formulations were evaluated for its drug content, mean particle size, 
encapsulation efficiency and drug loading. 
Determination of Drug content: 
Drug content of all formulation was found in range of 52.08% to 97.92% and 
its efficiency slightly decreases with increasing the HPMC content. The extent of 
loading influenced the particle size distribution of microspheres. When the 
distribution coefficient was high, efficiency of drug entrapment into microspheres 
was elevated. It is already reported that the size of microspheres depends upon 
various factors such as viscosity of the dispersed phase and dispersion medium, 
temperature, speed of stirring, amount and size of porous carrier, etc. So 
microspheres of desired size can be obtained by varying these factors.  
 Encapsulation Efficiency: 
The encapsulation efficiency of formulation F1 to F15 was carried out and 
found to be in a range 54.17% to 88.88 %. 
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Particle characteristics: 
SEM morphology: 
Scanning electron microphotographs showed that the microspheres were 
spherical with a smooth to rough surface (Fig 19). Pores were observed on the 
microsphere surface. 
Mean particle size:  
Increasing polymer concentrations (i.e., drugpolymer ratio from 1:1 to 1:4) 
increased microsphere size from 54.51to 92.62  61.42 μm  for eudragit rs 100, 
61.42 to 75.59μm for chitosan, 60.69 to 71.39μm for HPMC. However, in all cases, 
the increase was not significant .   
Increase in stirring rate from 600 rpm to 1400 rpm also seemed to have 
decreased microsphere size but the decrease was not significant .    
It was already cleared that if the size of microspheres is less than 55μm, 
release rate of drug will be high with reduced floating ability, the average particle 
sizes of microspheres were between 54.51 to 92.62 μm. It was observed that the 
mean particle size of the microspheres was significantly decreased with increase 
in the concentration of HPMC and reduces in the concentration of Eudragit RS100. 
It may be attributed to the forming of a thicker Eudragit RS100 layer with the 
increase of concentration of Eudragit RS100 in the medium 
In-vitro drug release of Sitagliptin phosphate microspheres:   
The dissolution studies was carried out in phosphate buffer for pH  7.2 for 
12 hours.  The invitro dissolution studies of all formulations were compared with 
pure drug.  The results of in vitro dissolution studies of all formulations form the 
sitagliptin microspheres were shown in figure 13 a to 13d.  
When compared the in vitro release profile of all formulations are 
significantly greater than that pure drug sitagliptin phosphate. 
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Formulations (F1E-F5E) using eudragit rs 100 at different ratios shown the 
percentage drug release of 99.37% at 7 hours, 95.08%at 8 hours,91.85%  at 9 
hours, 90.96% at 10 hours , 94.48% at 9 hours respectively.  
Formulations (F6EH-F510EH) using eudragit rs 100 along with HPMC E15 
at different ratios shown the percentage drug release of 90.46% at 8 hours, 
90.39%at 10 hours, , 92.63% at 12 hours , 96.07% at 9 hours, 92.20%  at  
10hours respectively.  
Formulations (F11ECH-F15ECH) using eudragit rs 100 along with chitosan 
at different ratios shown the percentage drug release of 88.26% at 8 hours, 
86.84%at 10 hours, , 87.34% at 12 hours , 88.44% at 9 hours,86.13%  at  10hours 
respectively.  
Drug release (for 1:3 drug/polymer ratio) after 12 h was in the rank order:   
HPMC > ethyl cellulose > chitosan>eudragit rs 100 (Fig 10), with the 
formulation prepared with HPMC E15 releasing approximately 92.63% of drug 
after 12 h.  
Increase in stirring speed from 600 rpm to 1400 rpm enhanced drug release 
rate. At 1600 rpm, complete drug release was observed except for chitosan 
microspheres. Fig 10 shows that the difference in drug release pattern among the 
various polymer types was not significant . 
Kinetic analysis: 
The release data was obtained for zero order, first order, higuchi model, 
Hixson crowell model, korsmeyer-peppas model. The correlation co-efficient of 
F1E to F15-ECH formulations for zero order, higuchi, Hixson-crowell  and first 
order equations was shown in table-7. Formulation F8-EH was found high 
correlation to zero order kinetics(0.899, figure 11a to 11c) rather than Hixson-
crowell models. 
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Higuchi model: 
The release kinetics of all the formulations is best fitted the higuchi model.  
Higuchi model with R2  values from 0.575 to 0.900.  From these higuchi model 
values, the release kinetics showed purely diffusion controlled. The release 
kinetics are shown in figure 16a to 16c. 
Korsmeyer –peppas model: 
The drug release was proportional to square root time, indicating that the 
drug release from polymeric microspheres was diffusion controlled.  The data 
obtained was also put in korsemeyer-peppas equation to find out release exponent 
(n values between 0.5 to 1.0 for anomalous transport corresponds to diffusion, 
erosion and swelling mechanism or mixed order kinetics(n value ranges from 
0.557 to 0.739), which describes the drug release mechanism by non fickian 
diffusion. 
SELECTION OF BEST FORMULATION: 
From the above results characterization, the best formulation of 
microspheres was selected showing particle size 62.28µm and in vitro drug 
release 92.63%  in 12 hours.  
PREPARATION  AND CHARACTERIZATION OF GEL: 
The sitagliptin phosphate microspheres were incorporated in a conventional 
carbomer gel formulation. Carbopol 934 is a commercial grade of carbomer. It is 
gelled by neutralization with triethanolamine. The formulated carbomer gel was 
very clear, transparent and elegant. Incorporation of gelatin microspheres resulted 
in finely dispersed particles in the gel system. A loading dose of the free drug was 
incorporated in the carbomer gel to produce immediate effect while drug-loaded 
microspheres are added to provide sustaining dose.  They were finally 
characterized for drug content, pH, gel strength, and spreadability and shown 
appreciable results.(Table-11) 
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Comparison of invitro dissolution studies of sitagliptin phosphate 
microsphere gel with marketed formulation: 
In-vitro drug release profile for sitagliptin phosphate of phosphate buffer of 
pH 7.2 for 12 hours, sitagliptin microsphere gel showed greater sustained 
action(12hours)  when compared with  sitagliptin marketed formulation(1hour).  
The results were shown in table-6d. 
Stability studies: 
          The formulations F15 was selected for stability studies on the basis of their 
encapsulation efficiency, drug content,  and high cumulative %drug release.  The 
stability studies carried out at 25oc (room temperature) and 40 oc/75%RH for the 
best formulation up to 30 days.  In 15 day time interval, the microspheres were 
analysed for drug content, encapsulation efficiency and cumulative % drug 
release.  The formulation showed not much variation in any parameter.  The 
results are shown in figure 20a-c.   
             
TABLE- 5a CALIBRATION OF SITAGLIPTIN PHOSPHATE IN 0.1N HCL 
S.NO CONCENTRATION (µg/ml) ABSORBANCE(nm 
1 5 0.011±0.0021 
2 10 0.031±0.0016 
3 15 0.05±0.0016 
4 20 0.07±0.0012 
5 25 0.089±0.0002 
     Regression value = 0.999605 
 
TABLE-5b CALIBRATION OF SITAGLIPTIN PHOSPHATE IN PHOSPHATE 
BUFFER PH  7.2 
S.NO CONCENTRATION (µg/ml) ABSORBANCE(nm 
1 5 0.021±0.0024 
2 10 0.045±0.0019 
3 15 0.069±0.0026 
4 20 0.092±0.0031 
5 25 0.116±0.0045 
Regression value=0.9999975 
 
 
 
 
TABLE -6 FORMULATION OF SITAGLIPTIN PHOSPHATE MICROSPHERES 
FORMULATION 
BATCH CODE 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 
SITAGLIPTIN 
(mg) 
0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
EUDRAGIT RS 
100 (mg) 
0.25 0.50 0.75 1.00 1.25 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
HPMC E-15 (mg) - - - - - 0.10 0.20 0.30 0.40 0.50 - - - - - 
CHITOSAN (mg) - - - - - - - - - - 0.10 0.20 0.30 0.40 0.50 
ACETONE  (ml) 6.00 9.00 12.0 15.0 18.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0 
TWEEN 80 (%) 0.10 0.30 0.50 0.70 0.90 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 0.70 
STIRRING 
SPEED(RPM) 
600 800 1000 1200 1400 1200 1200 1200 1200 1200 1200 1200 1200 1200 1200 
 
TABLE-7 DRUG CONTENT AND MEAN PARTICLE SIZE FOR SITAGLIPTIN 
PHOSPHATE MICROSPHERES 
 
S.NO 
FORMULATION 
CODE 
DRUG CONTENT 
(%) 
MEAN PARTICLE 
SIZE(µm) 
1. F1-E 60.42 92.62 
2. F2-E 70.83 85.52 
3. F3-E 81.25 76.35 
4. F4-E 83.33 56.35 
5. F5-E 75 54.51 
6. F6-EH 60.42 60.69 
7. F7-EH 66.66 61.63 
8. F8-EH 97.92 62.28 
9. F9-EH 81.25 66.54 
10. F10-EH 77.08 71.39 
11. F11-ECH 52.08 61.42 
12. F12-ECH 60.41 65.39 
13. F13-ECH 62.5 64.16 
14. F14-ECH 66.67 71.94 
15. F15-ECH 75 75.59 
 
 
 
 
 
 
 
TABLE- 8 PERCENTAGE YIELD, DRUG CONTENT, THEORETICAL DRUG 
LOADING, EXPERIMENTAL DRUG LOADING AND ENCAPSULATION 
EFFICIENCY OF SITAGLIPTIN PHOSPHATE MICROSPHERES 
 
S.NO F.CODE 
%YIELD 
(%) 
THEORETCIAL 
DRUG 
LOADING (%) 
EXPERIMENTAL 
DRUG LOADING 
(%) 
ENCAPSULATION 
EFFICIENCY (%) 
1. F1-E 39.91 50 70.47 56.25 
2. F2-E 46.74 33.33 49.02 68.75 
3. F3-E 56.79 25 33.93 77.08 
4. F4-E 63.39 20 26.29 83.33 
5. F5-E 69.86 16.67 18.55 77.77 
6. F6-EH 65.73 18.51 16.43 58.33 
7. F7-EH 67.24 17.24 17.98 70.13 
8. F8-EH 70.89 16.12 20.22 88.88 
9. F9-EH 72.79 15.15 16.62 79.86 
10. F10-EH 77.54 14.28 13.94 75.69 
11. 
F11-
ECH 
66.71 18.51 15.03 54.17 
12. 
F12-
ECH 
69.05 17.24 15.25 61.11 
13. 
F13-
ECH 
71.79 16.12 14.51 64.58 
14. 
F14-
ECH 
72.37 15.15 14.82 70.83 
15. 
F15-
ECH 
74.86 14.29 14.70 77.08 
 
 
 
TABLE 9a IN-VITRO DISSOLUTION PROFILE FOR SITAGLIPTIN PHOSPHATE MICROSPHERES 
 
TIME IN 
HOURS 
CUMULATIVE % DRUG RELEASE 
FORMULATION CODE- EUDRAGIT RS 100 
F1-E F2-E F3-E F4-E F5-E 
MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD 
1. 38.78 0.24 39.98 0.10 39.20 0.82 40.13 0.86 40.73 0.28 
2. 39.95 0.53 41.72 0.174 41.30 0.56 42.22 0.81 42.65 0.12 
3. 41.87 0.72 44.07 0.76 42.69 0.10 44.57 0.68 44.89 0.43 
4. 45.67 0.28 45.70 0.61 44.60 0.10 45.17 0.53 47.19 0.40 
5. 54.54 0.72 48.15 0.61 54.12 0.15 46.66 0.72 51.60 0.81 
6. 64.16 0.68 59.90 0.61 60.22 0.16 53.83 0.26 62.10 0.13 
7. 99.37 0.24 80.14 0.40 76.87 0.10 65.94 0.24 66.79 0.14 
8.   95.08 0.38 80.10 0.61 70.52 0.16 74.42 0.28 
9.     91.85 0.53 81.27 0.16 94.48 0.13 
10.       90.96 0.61   
11.           
12.           
 
 
TABLE-9b IN-VITRO DISSOLUTION PROFILE FOR SITAGLIPTIN PHOSPHATE MICROSPHERES 
TIME IN 
HOURS 
CUMULATIVE % DRUG RELEASE 
FORMULATION CODE- EUDRAGIT RS 100 WITH HPMC E15 
F6-EH F7-EH F8-EH F9-EH F10-EH 
MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD 
1. 38.31 0.51 37.30 0.27 37.94 0.53 37.82 0.81 39.31 0.60 
2. 39.14 0.61 38.18 0.16 38.92 0.54 39.60 0.10 40.34 0.10 
3. 39.99 0.61 40.63 0.54 40.56 0.10 41.34 0.16 43.11 0.10 
4. 43.18 0.61 42.72 0.53 42.51 0.61 43.01 0.10 44.85 0.61 
5. 45.66 0.57 43.86 0.46 43.25 0.61 45.21 0.61 45.81 0.44 
6. 57.84 0.12 45.53 0.16 44.39 0.90 61.46 0.80 47.80 0.56 
7. 80.88 0.61 49.93 0.30 45.38 0.40 80.45 0.58 54.86 0.22 
8. 90.46 0.49 59.69 0.14 50.92 0.44 96.07 0.17 60.58 0.21 
9.   79.50 0.53 61.93 0.24   78.72 0.68 
10.   90.39 0.10 70.37 0.28   92.20 0.21 
11.     87.06 0.21     
12.     92.63 0.59     
 
 
 
TABLE-9c IN-VITRO DISSOLUTION PROFILE FOR SITAGLIPTIN PHOSPHATE MICROSPHERES 
 
TIME IN 
HOURS 
CUMULATIVE % DRUG RELEASE 
FORMULATION CODE- EUDRAGIT RS 100 WITH CHITOSAN 
F11-ECH F12-ECH F13-ECH F14-ECH F15-ECH 
MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD 
1. 37.93 0.81 37.75 0.74 37.47 0.26 38.39 0.31 38.53 0.37 
2. 39.14 0.81 38.96 0.76 38.50 0.16 39.07 0.28 39.78 0.53 
3. 40.06 0.86 40.45 0.10 40.59 0.48 40.77 0.36 42.19 0.86 
4. 41.98 0.72 42.05 0.10 41.66 0.53 44.14 0.12 44.18 0.10 
5. 44.50 0.76 43.57 0.61 42.37 0.63 47.51 0.96 44.92 0.10 
6. 50.39 0.52 44.39 0.90 43.43 0.10 52.02 0.25 50.67 0.46 
7. 63.49 0.26 45.53 0.54 45.63 0.61 71.05 0.98 56.39 0.58 
8. 88.26 0.56 51.35 0.32 48.08 0.61 88.44 0.48 63.77 0.55 
9.   60.26 0.21 60.65 0.53   69.84 0.10 
10.   71.12 0.21 71.08 0.40   86.13 0.31 
11.   86.84 0.69 76.73 0.25     
12.     87.34 0.37     
 
 
TABLE-9d IN-VITRO DRUG RELEASE PROFILE FOR SITAGLIPTIN PHOSPHATE 
 
TIME IN 
HOURS 
CUMULATIVE % DRUG RELEASE 
COMPARISON FOR BEST RELEASE PROFILE 
GEL PURE TABLET F8-EH F13-ECH 
MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD MEAN ±SD 
1. 37.68 1.34 95.73 0.46 96.12 1.07 37.94 0.53 37.47 0.26 
2. 38.78 0.43     38.92 0.54 38.50 0.16 
3. 39.85 0.31     40.56 0.10 40.59 0.48 
4. 40.34 0.21     42.51 0.61 41.66 0.53 
5. 41.69 0.34     43.25 0.61 42.37 0.53 
6. 43.82 0.27     44.39 0.91 43.43 0.10 
7. 45.96 0.48     45.38 0.40 45.63 0.61 
8. 48.77 0.32     50.92 0.44 48.08 0.61 
9. 58.77 0.28     61.93 0.24 60.65 0.53 
10. 66.11 0.60     70.37 0.28 71.08 0.40 
11. 81.02 0.60     87.06 0.21 76.73 0.25 
12. 94.80 0.60     92.63 0.59 87.34 0.37 
 
 
TABLE-10  IN-VITRO RELEASE KINETICS OF SITAGLIPTIN PHOSPHATE MICROSPHERES 
FORMULATION 
CODE 
ZERO ORDER 
KINETICS 
FIRST ORDER 
KINETICS 
HIGUCHI MODEL 
KORSMEYER 
PEPPAS 
MODEL 
HIXON 
CROWEL 
MODEL 
R2 KO(h-1) R2 KO(h-1) R2 KH(h-1/2) R2 n2 R2 KHC(h-1/3) 
F1-E 0.775 9.877 0.776 -9.877 0.575 -0.366 0.557 0.362 0.575 -0.366 
F2-E 0.847 9.020 0.847 -9.020 0.782 -0.273 0.657 0.371 0.782 -0.273 
F3-E 0.897 8.199 0.897 -8.199 0.897 -0.236 0.779 0.394 0.897 -0.236 
F4-E 0.868 6.869 0.868 -6.869 0.871 -0.195 0.739 0.345 0.870 -0.196 
F5-E 0.860 7.654 0.886 -7.489 0.856 -0.233 0.639 0.386 0.856 -0.233 
F6-EH 0.852 8.878 0.852 -8.877 0.814 -0.249 0.589 0.306 0.814 -0.249 
F7-EH 0.785 5.542 0.786 -5.542 0.900 -0.153 0.639 0.331 0.731 -0.153 
F8-EH 0.899 5.551 0.830 -5.550 0.778 -0.256 0.637 0.331 0.777 -0.167 
F9-EH 0.835 7.848 0.835 -7.847 0.740 -0.240 0.637 0.369 0.740 -0.241 
F10-EH 0.816 6.416 0.816 -6.416 0.767 -0.182 0.654 0.318 0.766 -0.182 
F11-ECH 0.793 7.612 0.792 -7.611 0.734 -0.200 0.587 0.319 0.734 -0.200 
F12-ECH 0.786 5.142 0.785 -5.141 0.756 -0.134 0.619 0.283 0.756 -0.134 
F13-ECH 0.823 5.093 0.825 -5.093 0.813 -0.136 0.645 0.311 0.813 -0.136 
F14-ECH 0.791 6.722 0.790 -6.722 0.748 -0.179 0.605 0.308 0.748 -0.179 
F15-ECH 0.837 6.023 0.837 -6.025 0.836 -0.156 0.732 0.312 0.836 -0.157 
 
TABLE -11 CHARACTERIZATION OF GEL OF SITAGLIPTIN MICROSPHERES 
pH SPREADABILITY GEL STRENGTH DRUG CONTENT 
5.01 4.8(g.cm/second) 52 seconds 98.02% 
 
TABLE-12 STABILITY STUDIES  
S.NO 
FORMULATION 
CODE 
EVALUATION 
PARAMETERS 
 
BEFORE 
STORAGE 
Stored at 40°C ± 2°C 
and 75% ± 5% RH 
(AFTER STORAGE) 
For 15 
days 
For 30 
days 
1. F8-EH Drug content (%) 97.9 96.8 95.1 
2. F8-EH 
Encapsulation 
efficiency(%) 
88.88 86.9 85.8 
3. F8-EH 
% cumulative 
drug release(%) 
92.63 91.5 90.2 
 
  
 
 FIGURE-4a DETERMINATION OF λmax FOR SITAGLIPTIN PHOSPHATE 
USING PHOSPHATE BUFFER PH 7.2 at 267nm 
 
 
 
 
 
 
 
 
 
 
  
FIGURE 4b- CALIBRATION OF SITAGLIPTIN PHOSPHATE IN PHOSPHATE 
BUFFER PH  7.2 
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 FIGURE-4c DETERMINATION OF λmax FOR SITAGLIPTIN PHOSPHATE 
USING 0.1N HCL 
 
 
 
 
 
 
 
 
 
 
  
 
 
FIGURE 4d- CALIBRATION OF SITAGLIPTIN PHOSPHATE IN 0.1N HCL 
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 FIGURE -5a IR SPECTRA OF SITAGLIPTIN PHOSPHATE 
 
 
 
 
FIGURE 5b – IR SPECTRA OF EUDRAGIR RS 100 
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 FIGURE 5c- IR SPECTRA OF SITAGLIPTIN+EUDRAGIT RS 100+ HPMC E15+ 
CHITOSAN+CARBOPOL 934 
 
 
 
FIGURE 5d- IR SPECTRA OF SITAGLIPTIN FORMULATION (BEST) 
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SITAGLIPTIN FORMULATION
 FIGURE 6a – DSC THERMOGRAM OF SITAGLIPTIN PHOSPHATE 
 
 
 
FIGURE 6b- DSC THERMOGRAM OF SITAGLIPTIN BEST FORMULATION 
 
 
 
 
 
FIGURE 7- PERCENTAGE YIELD OF SITAGLIPTIN MICROSPHERES 
 
 
 
FIGURE -8 THEORETICAL DRUG LOADING FOR SITAGLIPTIN 
MICROSPHERES 
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FIGURE -9 EXPERIMENTAL DRUG LOADING FOR SITAGLIPTIN 
MICROSPHERES 
 
 
 
FIGURE-10 DRUG CONTENT FOR SITAGLIPTIN MICROSPHERES 
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FIGURE-11 ENCAPSULATION EFFICIENCY FOR SITAGLIPTIN 
MICROSPHERES 
 
 
 
FIGURE-12 MEAN PARTICLE SIZE FOR SITAGLIPTIN MICROSPHERES 
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FIGURE-13a COMPARISON OF INVITRO RELEASE PROFILE OF 
SITAGLIPTIN PHOSPHATE MICROSPHERES CONTAINING                 
EUDRAGIT RS 100 AT DIFFERENT RATIOS 
 
 
FIGURE-13b COMPARISON OF INVITRO RELEASE PROFILE OF 
SITAGLIPTIN PHOSPHATE MICROSPHERES CONTAINING                      
EUDRAGIT RS 100 WITH HPMC-E15 AT DIFFERENT RATIOS 
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FIGURE-13c COMPARISON OF INVITRO RELEASE PROFILE OF 
SITAGLIPTIN PHOSPHATE MICROSPHERES CONTAINING                
EUDRAGIT RS 100 WITH CHITOSAN AT DIFFERENT RATIOS 
 
 
FIGURE-13d COMPARISON OF INVITRO RELEASE PROFILE OF 
SITAGLIPTIN PHOSPHATE FOR SELECTION OF BEST FORMULATION 
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FIGURE-14a COMPARISON OF IN-VITRO ZERO ORDER RELEASE KINETICS 
OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                  
EUDRAGIT RS 100 AT DIFFERENT RATIOS 
 
 
FIGURE-14b COMPARISON OF IN-VITRO ZERO ORDER RELEASE KINETICS 
OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                       
EUDRAGIT RS 100 WITH HPMC E-15 RATIOS 
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FIGURE-14c COMPARISON OF IN-VITRO ZERO ORDER RELEASE KINETICS 
OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                
EUDRAGIT RS 100 WITH CHITOSAN RATIOS 
 
 
 
FIGURE-15a COMPARISON OF IN-VITRO FIRST ORDER RELEASE KINETICS 
OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                  
EUDRAGIT RS 100 AT DIFFERENT RATIOS 
 
 
0
10
20
30
40
50
60
70
80
90
100
0 5 10 15
%
C
U
M
U
LA
TI
V
E 
D
R
U
G
 R
EL
EA
SE
TIME IN HOURS
ZERO ORDER PLOT
F11-ECH
F12-ECH
F13-ECH
F14-ECH
F15-ECH
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
%
 D
R
U
G
 R
EM
A
IN
ED
TIME IN HOURS
FIRST ORDER PLOT
F1-E
F2-E
F3-E
F4-E
F5-E
FIGURE-15b COMPARISON OF IN-VITRO FIRST ORDER RELEASE KINETICS 
OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                       
EUDRAGIT RS 100 WITH HPMC E-15 RATIOS 
 
 
FIGURE-15c COMPARISON OF IN-VITRO FIRST ORDER RELEASE KINETICS 
OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                
EUDRAGIT RS 100 WITH CHITOSAN RATIOS 
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FIGURE-16a COMPARISON OF IN-VITRO HIGUCHI MODEL RELEASE 
KINETICS OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY USING                  
EUDRAGIT RS 100 AT DIFFERENT RATIOS 
 
 
FIGURE-16b COMPARISON OF IN-VITRO HIGUCHI MODEL RELEASE 
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FIGURE-17a COMPARISON OF IN-VITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY 
USING EUDRAGIT RS 100 AT DIFFERENT RATIOS 
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FIGURE-17b COMPARISON OF IN-VITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY 
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FIGURE-17c COMPARISON OF IN-VITRO KORSMEYER PEPPAS MODEL 
RELEASE KINETICS OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY 
USING EUDRAGIT RS 100 WITH CHITOSAN RATIOS 
 
 
 
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2
LO
G
 %
C
U
M
U
LA
TI
V
E 
D
R
U
G
 R
EL
EA
SE
LOG T
PEPPAS PLOT
F6-EH
F7-EH
F8-EH
F9-EH
F10-EH
0
0.5
1
1.5
2
2.5
0 0.2 0.4 0.6 0.8 1 1.2
LO
G
 %
C
U
M
U
LA
TI
V
E 
D
R
U
G
 R
EL
EA
SE
LOG T
PEPPAS PLOT
F11-ECH
F12-ECH
F13-ECH
F14-ECH
F15-ECH
FIGURE-18a COMPARISON OF IN-VITRO HIXSON CROWEL MODEL 
RELEASE KINETICS OF SITAGLIPTIN PHOSPHATE MICROSPHERES BY 
USING EUDRAGIT RS 100 AT DIFFERENT RATIOS 
 
 
 
FIGURE-18b COMPARISON OF IN-VITRO KORSMEYER HIXSON CROWEL 
MODEL RELEASE KINETICS OF SITAGLIPTIN PHOSPHATE 
MICROSPHERES BY USING EUDRAGIT RS 100 WITH HPMC E-15 RATIOS 
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FIGURE-19 SCANNING ELECTRON MICROSCOPY OF                           
SITAGLIPTIN MICROSPHERES 
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FIGURE 20-b STABILITY STUDIES FOR SITAGLIPTIN PHOSPHATE 
MICROSPHERES 
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FIGURE 20-C STABILITY STUDIES FOR SITAGLIPTIN PHOSPHATE 
MICROSPHERES 
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SUMMARY AND CONCLUSION 
 In this present study was to formulate and evaluate sustained release 
microsphere gel loaded  sitagliptin phosphate in order to maintain a 
sustained drug concentration in serum for longer period of time, which 
may result in enhanced absorption and thereby improved 
bioavailability. 
 The results of compatibility studies by infrared spectroscopy and 
differential scanning calorimetry showed no interaction between the 
drug and polymers. 
 The microgel of sustained release microspheres of sitagliptin 
phosphate were successfully prepared by non-aqueous solvent 
evaporation technique. 
 All formulations F1 to F15   micropheres were evaluated for particle 
size analysis mean particle size range 54.51 to 92.62 μm. 
 Mean particle size range of sitagliptin microspheres were in the range 
of suitable size range 
   The F8-EH shows the maximum drug content  values of 97.92% 
Percentage Encapsulation efficiency of the F8 – 88.88 %. As the 
polymer concentration was increased the drug entrapment efficiency 
% was increased due to increase in the viscosity of the solution. The 
present investigation state that if the drugs are soluble in the solvent 
system, it results in high drug encapsulation efficiency than that of 
dispersed in the solvent system. The elimination of the drugs from the 
prepared microspheres highly dependent on the concentration of the 
polymer used, as the amount of the polymer increased the 
encapsulation efficiency of the microsphere increased because of the 
good matrix formation.    
 Scanning electron microphotographs showed that the microspheres 
were spherical with a smooth to rough surface. 
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 In-vitro release study of all the formulations were showed a sustained 
drug release with increase in concentration of different rate retardant 
polymers (EUDRAGIT RS 100, HPMC E15, CHITOSAN). Dissolution 
rate of all the formulations were sustained when compared to pure 
drug. 
 The selected best formulation was formulated into gel using carbopol 
934 by loading sitagliptin phosphate microspheres in carbomer gel. 
 The dissolution study was carried out in phosphate buffer pH  7.2  for 
12 hours.  The formulations shows sustained release of drugs up to 
12 hours and all formulations showed more than 90% drug release. 
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CONCLUSION 
Sustained release microspheres of sitagliptin phosphate prepared with the 
rate retardant polymers successfully by the non-aqueous solvent evaporation 
technique. 
 From the results it was observed that drug: polymer ratio influences the 
particle size, drug content, encapsulation efficiency and in-vitro drug release of 
sustained release microspheres.    
The formulated microspheres showed good drug-loading. The gel 
formulation, which consisted of drug-loaded sitagliptin microspheres, showed 
sustained release of for 12 h, thus indicating their suitability for the sustained 
delivery of the drugs for the treatment of DM. However, further studies, including 
clinical tests are required to confirm the gel’s therapeutic efficacy.   
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